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DEVELOPMENT AND APPLICATION OF GADOLINIUM FREE CARDIAC 
MAGNETIC RESONANCE FIBROSIS IMAGING FOR MULTISCALE STUDY OF 
HEART FAILURE IN PATIENTS WITH END STAGE RENAL DISEASE 
 
Cardiac magnetic resonance (CMR) is a powerful tool to noninvasively 
image ventricular fibrosis. Late gadolinium enhancement (LGE) CMR identifies 
focal and, with T1 mapping, diffuse fibrosis. Despite prevalent cardiac fibrosis 
and heart failure, patients with end stage renal disease (ESRD) are excluded 
from LGE. Absence of a suitable diagnostic has limited the understanding of 
heart failure and obstructed development of therapies in the setting of ESRD. A 
quantitative, gadolinium free fibrosis detection method could overcome this 
critical barrier, propelling the advancement of diagnostic, monitoring, and therapy 
options. This project describes the development of a gadolinium free CMR 
technique and application for cardiac fibrosis measurement in patients with 
ESRD. 
 
Magnetization transfer (MT) occurs during standard cine balanced steady 
state free precession (bSSFP) CMR, where extracellular matrix protons 
exchange magnetization with water molecules. Extracellular water volume 
expansion, concomitant with fibrosis, reduces MT and subtly elevates signal 
intensity. Our technique, 2-pt bSSFP, extracts endogenous contrast sensitive to 
tissue fibrosis by obtaining pairs of high and low MT-weighted images and 
calculating normalized signal differences, denoted by ΔS/So. 
 
We tested 2-pt bSSFP in patients referred for CMR and found excellent 
agreement spatially with LGE and quantitatively with extracellular volume 
fraction. Diagnostic and clinical application of 2-pt bSSFP was comparable to 
LGE. We applied 2-pt bSSFP to patients with ESRD for multiscale comparison 
with correlates of fibrosis ranging from blood biomarkers to whole organ function. 
Patients with ESRD displayed hypertrophy with reduced contraction, but elevated 
ΔS/So and fibrosis. Some biomarkers correlated with both hypertrophy and 
fibrosis, highlighting the need to distinguish between hypertrophic and fibrotic 
remodeling. We monitored fibrosis over 1 year using 2-pt bSSFP in a cohort of 
 
 
patients with ESRD. ΔS/So and fibrotic burden increased substantially, despite 
minor changes in structure and function. 
 
Collectively these studies validate and apply 2-pt bSSFP for gadolinium 
free fibrosis CMR in patients with ESRD. While ventricular structure and function 
are commensurate with progression toward heart failure, it is now possible to 
specifically describe global and focal patterns of cardiac fibrosis in ESRD, along 
with comparisons to blood biomarkers which may lead to improved diagnostics 
and molecular treatment targets. 
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CHAPTER 1: INTRODUCTION 
 
Heart Failure 
Epidemiology, Etiology, and Clinical Presentation 
Heart disease is currently the leading cause of death in the United States 
[1]. The prevalence of heart failure remains high at over 5.5 million adults in the 
United States [2]. Over $20 billion in medical expenses are attributed to heart 
failure. By the year 2030, the projected prevalence of heart failure is expected to 
exceed 8 million Americans costing over $53 billion [3]. This is driven by both the 
increasing incidence in a growing elderly population and improved survival due to 
advances in detection and treatments [3].  
Heart failure is defined as the inability of the heart to pump enough blood 
to meet the metabolic demands of the body. The etiology and clinical features 
are complex. Heart failure can result from filling and/or ejection abnormalities, 
caused by conduction, structural and/or functional alterations in the pericardium, 
myocardium, endocardium, valves, or vasculature [4,5]. Signs and symptoms are 
similarly complex and not specific to heart failure. Patients may present with 
dyspnea, exercise intolerance, fatigue, and fluid retention, although their 
manifestations are highly varied [4,6]. Many patients with heart failure remain 
asymptomatic. 
The majority of signs and symptoms of heart failure are caused by 
reduced left ventricular (LV) function. In fact, LV ejection fraction (EF) of <35% or 
<40% is often used as a cutoff to classify heart failure with reduced EF (HFrEF) 
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versus heart failure with preserved EF (HFpEF) [4,6]. HFrEF, or systolic heart 
failure, comprises about half of the heart failure population and is better 
understood than HFpEF, or diastolic heart failure [5]. This cutoff is prognostic and 
often used for enrollment into randomized controlled clinical trials [5], meaning 
efficacy for new treatments has been shown in HFrEF patients only [4]. The 
major influence of the LV in heart failure development, prognosis, and treatment 
is the motivation for focusing this project on investigating the LV only. 
 
Cardiac Remodeling  
Cardiac remodeling is the alteration of the structure (geometry, shape, and 
mass) and ultimately physiological function (contraction and relaxation) of the 
heart [7]. Particularly in the LV, remodeling is now appreciated as an important 
determinant in the progression and severity of heart disease to heart failure. 
Remodeling is a physiologic or pathophysiologic process mainly affecting the 
myocytes, but also the interstitium, fibroblasts, collagen, and vasculature in the 
ventricle [7]. Causes include, but are not limited to, myocardial infarction, volume 
or pressure overload, and inflammation.  
Following initial myocardial infarct, myocyte necrosis leaves reduced 
cellular mass and an area of thinned LV wall. In the first hours to weeks, the 
infarct region typically undergoes disproportionate thinning and dilation, known 
as infarct expansion [8-10], with a loss of regional myocardial mass [11]. 
Chronically, whole chamber dilation may follow, leading to increased end 
diastolic (EDV) and end systolic volumes (ESV) while restoring myocardial mass 
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to pre-infarct levels [12,13]. Increased chamber volume leads to volume overload 
in remote areas, causing hypertrophy in non-infarct zones [9]. These remodeling 
events aid in the maintenance of ejection fraction [12] and cardiac output [14], 
despite reduced contractility of the infarct segments, but at the cost of increased 
chamber volumes. Some patients may eventually progress to noncompensatory 
dilation and remodeling which leads to reduced EF [14] and can proceed to 
HFrEF. 
Hemodynamic overload increases myocyte stretch, a mechanical signal 
that initiates a complex intercellular cascade leading to cardiomyocyte growth 
and hypertrophy [15]. Systemic hypertension leads to pressure overload, causing 
elevated LV wall stress. This is counteracted by increasing wall thickness and 
mass. The resulting structural pattern is labeled concentric hypertrophy, in which 
LV chamber size, EDV and ESV [16], and cardiac output are reduced [15]. 
Thickened walls may also be stiffer thus unable to relax and fill with blood, 
leading to diastolic heart failure. Another pattern of LV growth—eccentric 
hypertrophy—is characterized by increased chamber size in conjunction with 
increased LV mass [15,16]. Often caused by volume overload, the LV wall 
responds by dilating, allowing preserved cardiac output and relatively normal wall 
thickness [16]. A third pattern of remodeling—concentric remodeling—has been 
described as normal LV mass with increased wall thickness [16]. While mass is 
unchanged, the decrease in chamber size leads to reduced cardiac output. 
Overall LV mass increases, independent of body size, as measured by left 
ventricular mass index (LVMI) are prognostic of clinical events and cardiac death 
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[17,18]. To support hypertrophic cardiomyocytes and their coordinated 
contraction, connective tissues of the extracellular matrix must remodel in parallel 
[19]. While initially adaptive, this matrix remodeling process can become 
pathological and lead to increased deposition of collagen in conjunction with 
hypertrophy (see Cardiac Fibrosis below). 
Additional causes can lead to pathological remodeling similar to those 
described above. Dilated cardiomyopathy, for example, may be idiopathic or due 
to non-ischemic influences such as heredity or alcoholism [20]. Hypertrophic 
cardiomyopathy may also be idiopathic or inherited [7,21]. Following 
hemodynamic or injurious insult, however, remodeling is an adaptive process to 
maintain cardiac function. The transition from compensatory to maladaptive 




 In healthy hearts, cardiomyocytes are surrounded by a lattice-like matrix of 
proteins and molecules along with other cell types like cardiac fibroblasts [22]. 
This extracellular matrix provides a scaffold for shape and structure and is 
required for proper function of the ventricles by assisting conduction and force 
generation. The equilibrium of the extracellular matrix, which consists primarily of 
collagen type I, is responsible for maintaining proper cardiac stiffness for efficient 
contraction and relaxation [23]. Cardiac fibrosis occurs from the remodeling of 
extracellular matrix and subsequent increase in collagen deposition.  
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Similar to and often in conjunction with structural remodeling, collagen 
deposition is a compensatory process to maintain proper ventricular stiffness. 
This is evident in myocardial infarction where necrotic cardiomyocytes are 
replaced with collagen [24] to form a dense scar. Fibrotic tissue protects the 
ventricle from rupture [25] and increases stiffness to maintain pump function. 
This replacement fibrosis process is typically characterized by a dense, focal 
pattern of scar.  
 Reactive fibrosis is a progressive process that develops from an increase 
in collagen production by cardiac fibroblasts [26]. Unlike replacement fibrosis, 
reactive fibrosis is characterized by a diffuse interstitial distribution. Hypertension, 
diabetes [27], and aging [22] contribute to the expansion of extracellular matrix 
and subsequent collagen deposition. Pressure overload induced hypertrophy (as 
seen in hypertension [28]) and hypertrophic cardiomyopathy [29] are also 
associated with diffuse, reactive fibrosis. Fibrosis has also been identified in 
volume overload-induced ventricular dilation without ischemia [30] and in dilated 
cardiomyopathy [31]. As described previously, infarcted hearts may also develop 
hypertrophy in remote zones [9] requiring subsequent adaptation by the 
extracellular matrix. Thus increased collagen content may also arise in this non-
infarcted tissue of ischemic hearts [31,32], particularly in areas of hypertrophy.  
 While reactive fibrosis can occur simultaneously or subsequently in 
structural remodeling, there is discrepancy whether dilation or hypertrophy 
directly correlates with fibrosis. An increase in collagen content is not absolute in 
areas of hypertrophy following myocardial infarction [24] or hypertension [33]. 
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Septal thickness and overall heart size are common clinical indicators of 
hypertrophy and often used as surrogates for fibrosis, yet some have found a 
lack of association with fibrotic burden [33]. While fibrosis is presumed to follow 
hypertrophy, there is also evidence that fibrosis can actually precede some forms 
of hypertrophy [34]. Particularly in the context of hypertrophy, then, myocardial 
fibrosis is not directly explained merely by growing cardiomyocytes [33]. Other 
unknown factors must be contributing to the development of reactive fibrosis. 
Importantly, fibrosis can lead to ventricular stiffening [35,36], which 
impacts pump function. Progressive collagen deposit causes stiffening, which 
typically affects diastolic relaxation followed by systolic contraction [37]. Fibrosis 
also disrupts the syncytium formed by healthy cardiomyocytes by isolating 
bundles of cardiomyocytes and disrupting gap junctions. The physical separation 
and disconnection of cardiomyocytes slows conduction and wave propagation, 
increasing the susceptibility to conduction block, which can initiate reentry and 
arrhythmia [38]. Thus, increased fibrosis is linked to worsening heart failure, 
arrythmogenesis, mortality risk [33], and sudden cardiac death [39]. 
 
Chronic Kidney Disease and End Stage Renal Disease 
Epidemiology and Etiology 
Over 13% of the United States adult population has persistent reduction of 
kidney function, or chronic kidney disease (CKD) [40]. Commensurate with 
current national health epidemics, primary risk factors for CKD include diabetes, 
hypertension, cardiovascular disease, and obesity [40]. Likely due to these 
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comorbidities, Blacks/African Americans are disproportionately affected by CKD. 
The severity of CKD is categorized by stages based on estimated glomerular 
filtration rate (eGFR) and albumin clearance. Patients are diagnosed with CKD if 
eGFR <60 ml/min/1.73m2 or urine albumin/creatinine ratio >30mg/g over 
persistent measurements. Patients who reach eGFR<15ml/min/m2 are 
considered CKD Stage 5, or complete renal failure. At this point, patients may be 
classified as end stage renal disease (ESRD), which indicates that they require 
renal replacement therapy for survival [41].  
 ESRD affects over 600,000 American adults and lends over $87 billion to 
total Medicare costs [42]. While overall incidence has plateaued, incident cases 
in middle aged and especially elderly populations are on the rise [40,41]. The 
leading primary causes of ESRD are diabetes, hypertension, glomerulonephritis, 
and cystic kidney disease [40]. Diabetes and hypertension as primary cause of 




 Each year, over 100,000 patients begin renal replacement therapy for 
treatment of ESRD [40,42,43]. Of patients initiating renal replacement therapy, 
nearly 90% receive hemodialysis treatment, but peritoneal dialysis (9%) and 
kidney transplants (3%) are increasing [42], especially in younger patients [40]. In 
patients on hemodialysis, death rates are highest in the first year of treatment, 
then after a drastic drop at year 2, steadily increase over at least the next 5 years 
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[42]. Cardiovascular events are the leading cause of deaths in patients on 
hemodialysis for ESRD, encompassing over 50% of the known causes of death 
[44]. Within 3 years of ESRD therapy, only about 50% of patients are still alive 
[41].  
 
End Stage Renal Disease and Cardiac Risk 
 The term cardiorenal syndrome has been used to describe the combined 
failure of both heart and kidneys [45]. Five types have been identified based on 
the influence of and outcome in each organ. Cardiorenal Type IV comprises CKD 
as an independent cause of heart failure [45]. Renal dysfunction worsens 
hypertension, increases fluid retention, and elevates circulating uremic toxins. 
Thus, ESRD contributes to volume overload, pressure overload, and 
cardiomyopathy [46]. These are the fundamental causes of cardiac remodeling, 
resulting in eccentric hypertrophy, concentric hypertrophy, and dilation, 
respectively, and promote the transition toward heart failure and possibly death. 
In fact, cardiovascular disease is the leading cause of death in patients with 
ESRD [42] 
Hemodialysis exacerbates many cardiovascular risks in patients with 
ESRD. One in 4 patients on hemodialysis will die from sudden cardiac death [43]. 
For long term hemodialysis patients, risk of cardiovascular mortality is 10-20 
times greater than the general population [47]. Unique risk factors for sudden 
cardiac death include hyperphysiologic swings in electrolytes and blood volume 
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[48,49]. Extreme blood volume removal during hemodialysis may also lead to 
hypotension, cardiac stunning [50], and repeated ischemic events [45].  
 
End State Renal Disease and Cardiac Fibrosis 
Patients with ESRD almost ubiquitously develop dilation [51] and/or 
hypertrophic [52] remodeling but fibrosis is not certain. Hypertrophy seems to 
develop early in CKD, prior to hemodialysis initiation [53] and progresses with 
deteriorating eGFR [54]. Previous reports describe a varied but large 
proportion—up to 91% [55]—of hemodialysis patients who are hypertrophic [56-
58]. In hemodialysis patients, hypertrophy is associated with poorer systolic 
function [58] and worse prognosis. Elevated blood pressure and ventricular 
dilation—likely from chronic volume overload—associates with increased LV 
mass [56,57], making the interplay between patterns of structural remodeling 
complex.  
Myocardial infarction prevalence is about 14% in hemodialysis patients, 
yet cause of death is most often attributed to sudden cardiac death, not 
myocardial infarction [47]. While a fraction of patients on hemodialysis develop 
replacement fibrosis following myocardial infarction, a larger proportion develop 
reactive fibrosis, which can occur with or without infarct [59].  
Similar to the cardiac patient population, CKD patients can demonstrate 
fibrosis irrespective of hypertrophy [60]. It has been shown that diffuse fibrosis 
may not correlate with systolic function or low EF [58]. While an autopsy study 
revealed an association between fibrosis and hemodialysis vintage [61] (time of 
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hemodialysis treatment) others have not found a similar correlation [58]. It is 
understood that patients on hemodialysis with a greater fibrotic burden (>30% of 
tissue area) have significantly worse prognosis [51], despite the lack of 
association with systolic dysfunction. In fact, in a multivariate analysis including 
hypertension, diabetes, ejection fraction, LV dilation, and cardiomyocyte 
hypertrophy as predictors, only the percent area of LV fibrosis emerged as an 
independent predictor of cardiac death [51]. An experimental model in rabbits 
also linked induced renal failure to arrhythmias and increased fibrosis [62]. 
Therefore, cardiac fibrosis is an independent risk factor for death above and 
beyond the structural remodeling seen in patients with ESRD. As articulated by 
McCullogh et al., cardiac fibrosis is a common and significant substrate for pump 
dysfunction and sudden cardiac death due to arrhythmia, the two leading 
mechanisms of death in ESRD [45]. 
 
Measuring Cardiac Fibrosis  
Tissue Biopsy 
Since fibrosis is a crucial element in cardiac disease and heart failure, 
accurate measurement is essential for proper diagnosis, treatment selection, and 
survival—particularly in the ESRD population. The historical gold standard for 
fibrosis identification is collagen volume fraction measured by myocardial tissue 
biopsy. Biopsy studies in ESRD patients have identified cardiomyocyte 
hypertrophy along with replacement [50] and diffuse fibrosis [51,63,64]. 
Unfortunately, this technique is prone to falsely report the absence of fibrosis 
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[65], likely due to the heterogeneity of the disease. Additionally, clinicians must 
assume fibrotic content of non-biopsied regions from small tissue samples. Aoki 
et al. report a mean percent area of fibrosis in myocardial samples in 
hemodialysis patients that is only slightly elevated (22%) compared to controls 
(21%) [51], which highlights that wide distribution of fibrosis leaves biopsy 
susceptible to false underestimations of true, global fibrotic burden. The 
invasiveness of the biopsy procedure also renders it unsuitable for serial 
measurements, which is critical for monitoring the actively remodeling hearts of 
patients with ESRD. 
 
Echocardiography 
 Echocardiography is a widely available technology with the ability to 
rapidly acquire measurements of LV mass and monitor systolic and diastolic 
function. Due to the prevalence of LV hypertrophy in the ESRD population, 
echocardiography has been widely adopted for measurement of cardiac 
remodeling and dysfunction. Measures of mass and volume are obtained for 
assessment of hypertrophy and dilation as well as LV function assessed by EF 
[66]. Using deformation imaging, echocardiography can measure LV dysfunction 
through strain and strain rate measurement in radial, circumferential, and 
longitudinal directions to identify systolic dysfunction [67]. Diastolic dysfunction 
can be assessed by comparing early (E) and late (A) diastolic strain via the E/A 
ratio and is predictive of outcomes [67]. Location and extent of infarct patterns 
may be identified by wall reduced tissue velocity [66]. 
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 Due to the potential correlation between hypertrophy, dysfunction, and 
fibrosis, echocardiography has been extended to the assessment of fibrosis in 
patients with ESRD. The unique and hyperphysiologic hemodynamic variations 
experienced by patients with ESRD can influence the accuracy of 
echocardiography. Measurements via echocardiography depend on both loading 
conditions and an assumed symmetric geometry of the LV [52], which is 
problematic for the dynamically shifting blood volumes and remodeling ESRD 
heart. It has been shown that echocardiography systematically overestimates LV 
mass and volumes in patients on hemodialysis [52,68]. Since hypertrophy is 
often used as a correlate for fibrosis, this overestimation not only impacts the 
understanding of structural remodeling, but also the assumption of cardiac 
fibrotic burden in ESRD. While this noninvasive method is preferred over biopsy, 
echocardiographic functional biomarkers such as E/A ratio may be unable to 
distinguish cardiac fibrosis as measured by histology [51], leaving this technology 
unsuitable for fibrosis identification in patients with ESRD. 
 
Contrast Enhanced Cardiac Magnetic Resonance Imaging 
 Cardiac magnetic resonance imaging (CMR) with gadolinium contrast 
agents has emerged as the new clinical standard for detecting fibrosis, 
particularly following myocardial infarction, using a technique called late 
gadolinium enhancement (LGE) [69-71]. Gadolinium is an extracellular contrast 
agent, delivered intravenously. Upon perfusion into the myocardium, gadolinium 
accumulates in areas of expanded interstitial space, which occurs during the 
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development of fibrosis [72]. It shortens the T1 (longitudinal) relaxation of protons 
associated with nearby water molecules, leading to an increase in signal intensity 
in magnetic resonance imaging (MRI). Slower kinetics and increased 
concentrations of gadolinium in fibrotic areas can be detected as enhancement 
on images 5-20 min after contrast agent injection [72]. Thus, LGE creates 
contrast between fibrotic and healthy myocardial tissue, where gadolinium 
washes out more quickly. 
While adequate for identifying focal fibrosis, relatively low levels of signal 
enhancement preclude the identification of diffuse fibrosis by LGE [63]. 
Combining LGE with T1 mapping techniques allows for calculation of 
extracellular volume fraction and determination of diffuse fibrosis [73-76]. T1 
relaxation time is shortened in proportion to the local concentration of gadolinium. 
The absolute T1 time in all myocardial voxels is measured to expose subtle 
changes in gadolinium concentration due to interstitial volume expansion and 
fibrosis [72]. Gadolinium distributes into all extracellular fluid in the body, so by 
correcting for hematocrit, the extracellular volume (ECV) fraction of the 
myocardium can be calculated. ECV represents a quantitative measure of fibrotic 
burden and has been applied in a wide range of cardiac diseases [77] and 
validated with histological comparison of collagen volume fraction [63,78]. 
Increased ECV is also associated with mortality in cardiac patients [79]. 
Shortened post-contrast T1 times and increased ECV, consistent with diffuse 




Contrast enhanced CMR plays an important role in tissue characterization 
and therefore differential diagnosis for cardiac patients with a wide variety of 
pathologies [72]. Reactive fibrosis in non-infarcted myocardium as measured by 
ECV is prognostic and has been associated with heart failure and death, 
independent of EF [81]. ECV measurement of fibrosis may also add incremental 
prognostic value on top of the well-established clinical risk factors for heart failure 
such as reduced EF, renal dysfunction, heart failure severity, and age. 
 Contrast enhanced CMR has been used to define patterns of fibrosis in 
patients with ESRD. Schietinger et al. described prevalent enhancement at LGE 
in hemodialysis patients, specifically identifying 3 patterns of fibrosis: (1) 
transmural enhancement consistent with an infarct pattern, and the more 
frequent non infarct-related (2) circumferential, diffuse enhancement, and (3) 
focal enhancement of the midwall [59]. In this study, LGE correlated with 
hypertrophy and systolic dysfunction on a global and segmental level, while a 
nonsignificant trend emerged for LGE and hemodialysis vintage. In a similar 
study, Mark et al. described 2 patterns of LGE, corresponding to ischemic 
(replacement) and non-ischemic (reactive) causes with high prevalence in ESRD 
patients [58]. Either type of LGE correlated with greater LV mass and dilation. 
Focal LGE associated with systolic dysfunction, while diffuse fibrosis did not. It is 
clear that a high rate of cardiac fibrosis is present in the ESRD population with 
varying structural and functional correlates. 
 In 2006, the U.S. Food and Drug Administration (FDA) issued several 
public health advisories resulting in updated product labeling and exclusion of 
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patients with renal insufficiency from gadolinium based imaging techniques 
[82,83]. These warnings resulted from the observation of nephrogenic systemic 
fibrosis in patients with ESRD supposedly caused by gadolinium [84] . Further 
evidence has established a causative role for gadolinium in the development of 
nephrogenic systemic fibrosis [84-87]. Despite the overwhelming benefits of LGE 
CMR for the identification of fibrotic burden and patterning, it is now unsuitable 
for use in patients with ESRD.  
Given the severe limitations in direct fibrosis measurement, the current 
dogma leans on the potential correlation between fibrosis and hypertrophy or 
dysfunction to predict fibrosis in patients with ESRD. The field has now reverted 
to non-contrast CMR or echocardiographic measurements of increased 
myocardial mass and reduced strain as surrogate measures of fibrosis. 
 
Non Contrast Cardiac MRI 
 Native T1 mapping without gadolinium is emerging as a non-contrast 
technique for tissue characterization [88,89], with valuable application for patients 
with ESRD [90]. As mentioned previously, T1 relaxation time measures the 
longitudinal relaxation of protons associated with water molecules. T1 is 
calculated using a curve-fitting algorithm based on samples taken at multiple 
inversion times [91]. The interstitial expansion occurring concomitantly with 
fibrosis development leads to an increase in extracellular water fraction, which 
can be detected as lengthened T1 times compared to healthy tissue. Modified 
Look-Locker inversion recovery (MOLLI) sequences are now widely used to 
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measure and map native T1 relaxation in a single acquisition during in CMR [92]. 
Using a threshold technique, native T1 mapping can distinguish infarcted tissue 
from normal tissue, in agreement with LGE, to identify replacement fibrosis [93]. 
Maps of T1 relaxation time allow both visual and quantitative analysis of fibrosis 
and have been correlated with histology [94] and contrast enhanced CMR 
measures of ECV [95,96]. T1 mapping in non-ischemic cardiomyopathy was 
correlated with dilation, ECV, and dysfunction [97], revealing a potential 
prognostic value for native T1 mapping. Others have shown no correlation 
between native T1 and histology [63] or calculation of ECV [98] though.  
 In a large study of patients with early CKD but not yet on dialysis, native 
T1 was increased and correlated with reduced strain but not LV mass [60]. 
Smaller reports of myocardial native T1 studies in patients on hemodialysis for 
ESRD are beginning to emerge [90,99]. Rutherford et al. demonstrated 
prolonged native T1 times along with hypertrophy and reduced strain in patients 
on hemodialysis [90]. Elevated T1 correlated with ventricular mass but not 
reduced strain. A recent case report also demonstrated the identification of non-
ischemic, reactive fibrosis patterns in one hemodialysis patient [99], 
demonstrating the utility of native T1 to identify specific patterns of fibrosis. 
Larger studies are warranted to investigate the role of T1 mapping in 
hemodialysis patients and its correlation with other cardiac remodeling 
measures. 
T1 mapping sequences are highly variable across centers resulting in 
varied reports of healthy myocardial T1 times [100]. T1 times in disease states 
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may be even more variable than healthy populations [101], leading to uncertainty 
in the accuracy for fibrosis identification. Ongoing efforts aim to standardize 
acquisition procedures and improve accuracy of normal myocardial T1 times so 
comparisons between sites and studies are more robust [96,100,102]. Heart rate 
variability, a common occurrence in ESRD, is a concern in T1 mapping, 
especially for long T1 values [91]. Additionally, the need to sample over multiple 
inversions, through a number of cardiac cycles, requires aggressive motion 
correction to be employed [103]. Due to motion correction artifacts, T1 
quantitative analysis has been predominantly limited to the interventricular 
septum [94,95,104]. It is known that patients on hemodialysis also tend to 
develop anemia which can exacerbate hypertrophy [105] and arbitrarily elevate 
native T1 times. Without correction for hematocrit, T1 mapping may not be an 
accurate fibrosis measurement option in this group. 
 Another non-contrast technique—magnetization transfer (MT) MRI—is 
emerging for myocardial tissue characterization. During standard clinical imaging 
using cine balanced steady state free precession (bSSFP) MRI, the transfer of 
saturated magnetization from extracellular matrix macromolecules to the 
surrounding bulk water occurs through a process called magnetization transfer 
(MT) [106], which reduces the myocardial signal intensity [107,108]. Expansion of 
extracellular water volume, which occurs concomitantly with progression of 
fibrosis, causes reduction in MT and subtle elevation of myocardial signal 
intensity. This endogenous contrast mechanism can be exploited for gadolinium 
free CMR fibrosis imaging.  
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 Simple visual identification of these myocardial signal elevations is 
challenging because of the subtle differences between healthy and fibrotic tissue. 
Advanced analysis of bSSFP images is required to extract the differences in MT 
caused by fibrosis. Two images with high and low MT-weighting are required. 
MT-weighting can be modulated by altering the radiofrequency (RF) pulse 
duration or flip angle such that long RF pulse duration or high flip angles (to a 
threshold) generate greater amounts of MT [108]. A pair of images is acquired 
with and without an off-resonance RF pulse [109] or at low and high flip angles to 
produce weak and strong MT effects, respectively. Effects of MT are typically 
measured as a ratio of signal intensity (SI) and presented as a percent following 
the formula: MT ratio=(SIweakMT – SIstrongMT )/ SIweakMT x100% [107]. Voxel-wise 
maps of MT ratio are generated to visually represent the alterations in myocardial 
MT allowing quantitative analysis per segment, slice, or whole ventricle. Notably, 
since MT-CMR is conducted using standard clinical bSSFP images, concurrent 
assessment of ventricular tissue characterization, structure, and function is 
possible. 
 MT effects have been investigated in select studies for cardiac fibrosis 
identification. In an experimental myocardial infarction model in rats, nuclear 
magnetic resonance measured the reduction of MT in acute and chronic 
myocardial infarction [110]. Vandsburger et al. described the identification and 
monitoring of scar formation by measurement of reduced MT ratio following 
induced myocardial infarction in mice [111]. MT-CMR showed excellent spatial 
association with LGE in this model. A study by Weber et al. in human participants 
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demonstrated uniform MT ratio in healthy myocardium, decreased MT ratio in 
infarcted tissue, and strong spatial agreement with LGE [108]. MT-CMR shows 
substantial promise for gadolinium free myocardial fibrosis measurement in 
patients with ESRD. The ability to combine structural, functional, and tissue 
characterization measurement in a single imaging technique means MT-CMR 
may be the key to multiscale study of fibrosis and its association with ventricular 
remodeling and dysfunction in hemodialysis patients with ESRD. 
 
Summary 
Patients with ESRD experience unique risk factors of heart failure and 
sudden cardiac death, unlike the general cardiac patient population. Clinical 
predictors of heart failure and sudden cardiac death are well established for 
cardiac patients but are complicated by comorbidities and unique exposures 
introduced by ESRD and hemodialysis treatment. Though these patients are 
highly attended in frequent hemodialysis treatment, the understanding of heart 
failure and sudden cardiac death in patients with ESRD remains obscure. 
Patients with ESRD, clearly suffer from a unique cardiomyopathy that is linked to 
their complex disease and treatment states. The current dogma treats 
hypertrophy or reduced strain as reliable surrogate measures of cardiac fibrosis 
in patients on hemodialysis. Conflicting evidence in a variety of studies illustrates 
the complex interaction and independence between structural remodeling, 
contractile dysfunction, and fibrosis while highlighting the inappropriateness of 
these dogmatic surrogate measures for fibrosis identification. While highly 
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related, hypertrophy, strain, and fibrosis should be treated as separate 
manifestations of a multifaceted disease. 
The exclusion of patients with ESRD from gadolinium enhanced CMR 
greatly hinders the capacity to safely identify and monitor fibrosis. Absence of a 
suitable cardiac fibrosis diagnostic has limited the understanding of heart failure 
in the setting of ESRD and obstructed development and testing of potential 
therapies in this unique population. Development of a gadolinium free and 
quantitative method of fibrosis detection could overcome this critical barrier and 
present better diagnostic and monitoring options to propel the development of 
targeted therapies. Accurate and safe measurement of fibrotic burden and 
distribution could inform appropriate pharmaceutical interventions or serve as 
selection criteria for alternative treatments such as radiofrequency ablation and 
implantable cardioverter-defibrillator to prevent arrhythmias and ultimately reduce 
the risk of sudden cardiac death in patients with ESRD. The following project 
describes the development of a gadolinium free, MT-CMR technique and its 
application for cardiac fibrosis measurement and monitoring in patients with 
ESRD.  
 
Copyright © Tori Ann Stromp 2016  
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CHAPTER 2: GADOLINIUM FREE CARDIAC MAGNETIC RESONANCE 
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Background: MRI of ventricular structure and function is widely performed using 
cine balanced steady state free precession (bSSFP) MRI. The bSSFP signal of 
myocardium is weighted by magnetization transfer (MT) and T1/T2-relaxation 
times. In edematous and fibrotic tissues, increased T2 and reduced MT lead to 
increased signal intensity on images acquired with high excitation flip angles. We 
hypothesized that acquisition of two differentially MT-weighted bSSFP images 
(termed 2-point bSSFP) can identify tissue that would enhance with gadolinium 
similar to standard of care late gadolinium enhancement (LGE).  
 
Methods: Cine bSSFP images (flip angles of 5º and 45º) and native-T1 and T2 
maps were acquired in one mid-ventricular slice in 47 patients referred for 
cardiac MRI and 10 healthy controls. Afterwards, LGE images and post-contrast 
T1 maps were acquired and gadolinium partition coefficient (GPC) was 
calculated. Maps of ΔS/So were calculated as (S45-S5)/S5*100 (%), where 
Sflip_angle is the voxel signal intensity.  
 
Results: Twenty three patients demonstrated areas of myocardial hyper-
enhancement with LGE. In enhanced regions, ΔS/So, native-T1, T2, and GPC 
were heightened (p<0.05 vs. non-enhanced tissues). ΔS/So, native-T1, and T2 all 
demonstrated association with GPC, however the association was strongest for 
ΔS/So. Bland-Altman analysis revealed a slight bias towards larger volume of 
enhancement with ΔS/So compared to LGE, and similar transmurality. Subjective 
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analysis with 2-blinded expert readers revealed agreement between ΔS/So and 
LGE of 73.4%, with false positive detection of 16.7% and false negative detection 
of 15.2%.  
 
Conclusions: Gadolinium free 2-point bSSFP identified tissue that enhances at 
LGE with strong association to GPC. Our results suggest that with further 






Cardiac magnetic resonance imaging (CMR) has become a reference 
standard modality to image ventricular structure, contractile function, and 
perfusion [112]. Combined with intravenous administration of gadolinium contrast 
agents, late gadolinium enhancement (LGE) – CMR has become the standard of 
care to identify myocardial edema, necrosis, and focal fibrosis. The presence of 
LGE correlates with significantly increased risk of adverse cardiac events and 
mortality [113]. Recent studies that identify diffuse fibrosis through measurement 
of gadolinium partition coefficient (GPC) or the extracellular volume fraction 
(ECV) [77,114] have similarly demonstrated a strong correlation between diffuse 
fibrosis and increased mortality [115]. However, residual concerns surrounding 
gadolinium and nephrogenic systemic fibrosis [116] have spurred the 
development of gadolinium free methods to identify diseased myocardium.  
 Both edematous and fibrotic myocardium are characterized by an 
increased extracellular volume fraction, which results in lengthened native-T1 
and T2-relaxation times compared to healthy myocardium. These changes have 
been used to identify edema in acute MI [117,118] and fibrosis in select 
cardiomyopathies [119-121]. Recent studies using native T1-mapping to identify 
fibrosis are highly promising [122-124]. However, measured myocardial T1-
relaxation times vary between T1-mapping pulse sequences [125] and 
myocardial regions [126], require special sequence modifications to reduce 
arrhythmia sensitivity [127], and reconstruction of T1-maps requires motion 
correction [128] that has limited some prior measurements to the septum 
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[119,121,129,130]. In contrast, cine balanced steady state free precession 
(bSSFP) is ubiquitously used to image ventricular structure and function. While 
weighting of the bSSFP signal by a factor of √T2/T1 is established, modulation of 
the bSSFP signal by magnetization transfer (MT) from extracellular matrix 
macromolecules has only recently been understood [131,132]. Specifically, 
myocardium characterized by increased ECV demonstrates reduced MT 
compared to healthy myocardium, as demonstrated in a prior study of acute-MI 
[131]. However, whether MT-weighted CMR can be used to identify tissues that 
would enhance with gadolinium across a range of cardiomyopathies similar to 
LGE has not been examined. 
We hypothesized that acquisition of bSSFP cine image sets with different 
MT-weighting (termed 2-point bSSFP) could combine the changes in signal 
intensity due to both lengthened T1/T2-relaxation and reduced MT to identify 
tissue that would enhance with gadolinium in close agreement to LGE. We 
compared tissue characterization with 2-point bSSFP, native-T1 and T2-mapping 
to LGE in 47 patients referred for cardiac MRI at our institution. Our results 
demonstrate robust agreement between gadolinium free 2-point bSSFP imaging 









Patient Selection, Ethics, Consent and Permissions 
 Fifty non-consecutive patients referred for clinically indicated CMR with 
gadolinium contrast were prospectively enrolled, however 3 were excluded due 
to inability to maintain breath-holds. All patients referred for CMR with gadolinium 
contrast at our institution over a six month period were approached for study 
participation, with the forty seven included in the study representing those that 
consented to participate. Afterwards, ten healthy age-matched controls were 
recruited but did not receive gadolinium. The research protocol was approved by 
our institutional review board (IRB 13-0914-F2L) and informed consent was 
obtained from all subjects for participation and publication of findings. 
Demographic characteristics are summarized in Table 1. Clinical CMR reports 
were used to obtain ejection fraction (EF), end-diastolic volume (EDV), and CMR 
diagnosis.  
 
Cardiac MRI Protocol 
CMR was performed on a 1.5T Siemens MAGNETOM Aera scanner 
(Siemens Medical Imaging Solutions, Erlanger, Germany) using an 18 channel 
body coil and 12 channel spine coil. A short-axis stack of bSSFP cine images 
were obtained with prospective ECG triggering to cover the entire heart (TE: 
1.2ms TR: 3.2ms, bandwidth: 930Hz, field of view: 260x260mm, slice thickness: 
8mm, flip angle: 50°, 256x256matrix, GRAPPA 2), from which one mid-
ventricular slice was identified for further imaging. The signal intensity of bSSFP 
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images acquired with high excitation flip angles and short repetition times is 
heavily weighted by MT, T1 and T2, while identical images acquired with low flip 
angles reflect proton density weighting with minimal contributions from MT. In the 
identified slice, pairs of bSSFP cine images were acquired with excitation flip 
angles of 5° (proton density reference) and 45° (MT, T1, T2-weighted) during 
end-expiratory breath-holds. Native myocardial T1-relaxation times were 
assessed using a modified Look-Locker imaging (MOLLI) sequence (5(3)3, 
TE:1.1ms, TR:2.7ms, flip angle:35°, bandwidth:1085Hz, field of view:272x 
272mm, slice thickness:8mm, 256 matrix with 66% phase resolution, partial 
Fourier transform 7/8, GRAPPA 2). T2-relaxation times were assessed using a 
gradient echo readout (T2 preparations of: 0ms, 25ms, 55ms with 3 heart beat 
recovery in between, TE:1.1ms, TR:3.2ms, bandwidth:1184Hz, field of 
view:272x272mm, slice thickness:8mm, 192 matrix with 75% phase resolution, 
partial Fourier transform 6/8, GRAPPA 2) in the same short axis slice during 
diastasis. Afterwards, gadolinium (0.2mmol/kg Gd-DTPA) was administered 
intravenously as a bolus (rates ranged from 2ml/s to 5ml/s) and after 15 minutes 
LGE images were obtained using segmented gradient recalled echo inversion 
recovery (TE:3.2ms, TR:8.3ms, flip angle:25°, Bandwidth:140Hz) with inversion 
time set to optimally null the myocardium. Finally, post-contrast MOLLI 
(4(1)3(1)2, TE: 1.1ms, TR: 2.7ms, flip angle: 35°, field of view: 272 x 272mm, 
GRAPPA 2) images were obtained in the same slice position as pre-contrast 





Maps of T1 and T2-relaxation times were automatically reconstructed after 
motion correction using non-rigid body correction. The reproducibility of breath-
hold position and the degree of mis-alignment between 5° and 45° scans was 
assessed via calculation of the DICE similarity coefficient for both complete 
images and segmented images in which only the heart was included. 2-point 
bSSFP data was analyzed by calculating the normalized change in signal 
between images as (ΔS/So)i=[(S45-S5)/S5]i, where S45 and S5 represent the signal 
intensity for 45° and 5° excitations respectively for each cardiac phase (i). For 
each patient ΔS/So maps from 3 diastolic phases without cardiac motion were 
averaged together to reduce random noise. Maps of GPC were calculated as 
GPC=(ΔR1,myocardium/ΔR1,blood) from reconstructed T1-maps. 
Data from patients receiving gadolinium were divided and analyzed in a double-
blinded manner. An SCMR level-III reader (SWL) used a custom designed 
MATLAB script to segment the myocardium and define a non-enhanced region of 
interest (ROI) in each LGE image. Myocardial voxels with signal intensity greater 
than 5 standard deviations (SD) above the mean of the defined ROI were 
classified as enhanced at LGE. Maps defining LGE-enhanced and non-enhanced 
regions were saved, transmitted to MHV, and used to segment ΔS/So, native-T1, 
T2, and GPC maps. To avoid partial volume errors and account for minor 
differences in spatial resolution, endocardial and epicardial borders were slightly 
adjusted to remove the blood pool and pleural space. Measurements in healthy 
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controls and patients without LGE-enhancement were performed over all voxels 
in the myocardium.  
In data acquired from patients demonstrating enhancement at LGE, the 
enhanced area was calculated as the percentage of all myocardial voxels 
classified within the enhanced ROI. To calculate the enhanced area from maps 
of ΔS/So, a threshold value of 197% (representing the mean + 3 standard 
deviations of the mean from the healthy control cohort) was applied and used to 
calculate the fraction of myocardial voxels above the threshold. Transmurality 
was calculated as the percentage of enhancement along the radial direction at 
the center of the area of enhancement for LGE and ΔS/So maps. 
Figures were prepared using a median filter with a 3x2 kernel. The color 
scheme for maps of ΔS/So and native-T1 used in Figures 2.1-2.5 has been 
designed to emulate LGE, with non-enhanced tissue appearing dark, enhanced 
tissue appearing bright, and tissue that would demonstrate diffuse “gray” 
enhancement appearing red/yellow.  
 
Subjective Assessment by Blinded Readers 
 Subjective assessment of 2-point bSSFP in comparison to LGE was 
performed by two blinded readers with 1 and over 10 years’ experience. All 
ΔS/So maps and LGE images were compiled separately and randomized. The 
readers were asked to identify the presence, location, and type (focal vs. diffuse) 





 Numeric data are summarized as mean ± SD. For outcome variables we 
used Version 9.3 of SAS software (SAS Institute, Cary NC) to fit a linear mixed 
model comparing mean levels across four groups of heart tissue: healthy controls 
(Group I), patients without LGE-enhancement in the imaged slice (Group II), non-
enhanced regions of interest from patients with LGE-enhancement (Group III), 
and enhanced regions of interest from patients with LGE-enhancement (Group 
IV). We included random effects for subjects to account for correlations between 
measurements on non-enhanced and enhanced tissue from the same patient 
with LGE-enhancement. Linear contrasts were used for pairwise comparisons. 
Demographic variables were analyzed using SPSS (IBM Corp., 2013). The 
Shapiro-Wilk method was used to test normality of numeric data. Age, body 
mass index (BMI), and race were compared across all participants using the 
Kruskal-Wallis method. Fisher’s exact tests were used to compare gender across 
all participants and CMR diagnosis between the two patient groups. Differences 
in EF were compared via Mann-Whitney and EDV was analyzed by student’s t-
test. Statistical significance in pairwise comparisons was defined by a p-value < 
0.05 divided by the number of comparisons to control Type I testing error through 
Bonferroni adjustment. Otherwise, a p-value<0.05 defined statistical significance.  
 
Results  
Demographics and Ventricular Structure and Function 
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 Amongst 23 patients who demonstrated LGE-enhancement in the imaged 
slice, EDV trended higher and EF trended lower compared to patients who did 
not demonstrate LGE-enhancement (Table 2.1). There were no significant 
differences in age or BMI between patients with and without LGE enhancement. 
Control participants differed only in BMI compared to patients (p<0.001 for all). 
 
MR Tissue Characterization 
 The DICE similarity coefficient measured across all patients was 0.995 ± 
0.004 when comparing entire 5° and 45° images. Comparison of the same 
images following segmentation of only the heart revealed a DICE similarity 
coefficient of 0.991± 0.015. Representative bSSFP images and maps of ΔS/So in 
a healthy control subject and a patient without LGE-enhancement revealed 
uniformly low ΔS/So values across both hearts (Figure 2.1). In patients with acute 
(Figure 2.2-2.3) and chronic MI (Figure 2.4), CMR tissue characterization with 2-
point bSSFP demonstrated heightened ΔS/So values in close spatial agreement 
with LGE-CMR enhancement patterns. Representative images acquired in two 
patients with non-ischemic dilated cardiomyopathy demonstrate the accurate 
detection of fibrotic tissue using 2-point bSSFP (Figure 2.5). Elevated native T1-
relaxation times were also observed in agreement with LGE following MI (Figures 
2.2 and 2.4).  
Average myocardial ΔS/So, native-T1 and T2 relaxation-times were 
significantly higher in LGE-enhanced regions (Group IV) compared to all non-
enhanced regions (Groups II and III) and healthy controls (Group I, Figure 2.6). 
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The mean of the standard deviation of ΔS/So values amongst healthy controls 
was 27.1 ± 8.1 (%) in absolute terms. Segmentation of the heart into twelve 
equal circumferentially spaced sectors revealed moderately lower average ΔS/So 
values (118.8 ± 14.7 (%)) in the anterior-lateral wall compared to the rest of the 
myocardium. Additionally, GPC was significantly elevated in LGE-enhanced 
regions (Figure 2.6). Native-T1 and T2-relaxation times and ΔS/So did not differ 
significantly between non-enhanced myocardium in patients (Groups II and III) 
and healthy controls (Group I, Figure 2.6). Native-T1, T2 and ΔS/So all 
demonstrated strong association with GPC (Figure 2.7).  
Quantification of the percent of myocardium classified as enhanced at 2-
point bSSFP demonstrated a strong association (R2 = 0.84) with the percent of 
myocardium classified as enhanced at LGE (Figure 2.8), however a slight bias 
towards over-estimation of the enhanced area in patients with a higher 
percentage of enhancement was observed. Bland-Altman analysis (Figure 2.8) 
revealed a coefficient of covariance of 0.204. Measurement of the transmurality 
of enhancement was similar between 2-point bSSFP and LGE (R2 = 0.73), and 




 Analysis of ΔS/So maps and LGE images by 2 blinded readers revealed 
an average agreement of 73.4% between methods. Among the patients 
demonstrating enhancement at LGE, the extent of enhancement on ΔS/So maps 
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was identified as the same in an average of 67.2% of individuals. The extent of 
enhancement was identified as greater in ΔS/So maps in 20.8% of individuals, 
and smaller in ΔS/So maps in 12.0% of individuals. An average of 4 out of 24 
patients in which enhancement was not identified in LGE images were classified 
as demonstrating enhancement on ΔS/So maps (Figure 2.9). Among the 23 
patients demonstrating enhanced tissue at LGE, an average of 3.5 were 
classified as normal by readers interpreting ΔS/So maps (Figure 2.10). In all such 
cases, enhancement patterns were consistent with small sub-endocardial 
enhancement at LGE.  
 
 Discussion 
 In this study we present a new 2-point bSSFP method for gadolinium free 
CMR. In 47 patients undergoing clinical LGE examination, 2-point bSSFP 
demonstrated a strong association between elevated ΔS/So and enhanced 
regions in LGE across a range of cardiomyopathies. Further, 2-point bSSFP 
demonstrated similar results to mapping of native-T1 relaxation times. 
Importantly, in this study we used a relatively simple method to generate MT 
contrast in bSSFP images. However, MT contrast can be further enhanced 
through the use of additional MT-preparation schemes, potentially increasing the 
sensitivity of CMR tissue characterization with MT contrast.  
 Heightened steady state signal in edematous cardiac tissue occurs in 
bSSFP images acquired with a short repetition time and high flip angle. In a 
study by Zhou et al. [132], edematous myocardium was visualized as hyper-
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intense on bSSFP images following ischemia-reperfusion injury in dogs. By 
comparison to T2-prepared SSFP images, the authors concluded that edema 
contrast in bSSFP was dominated by changes in MT and proton density (65%), 
with altered relaxation times having a more modest effect (35%). Similarly, 
Kumar et al. [133] observed a 50% increase in bSSFP signal in infarcted tissue in 
dogs and patients with acute MI. While we observed increased signal intensity in 
edematous areas on bSSFP images, we found that visualization required 
significant contrast adjustments and resulted in noisy images (Figure 2.3). In 2-
point bSSFP, changes in signal intensity on standard bSSFP cine images caused 
by increased T2 and reduced MT in tissue that enhances at LGE were extracted 
by normalization to images acquired with a 5° flip angle (proton density 
weighted). Measurement of ΔS/So, which was elevated in enhanced tissue in 
patients with acute MI, was consistent with signal intensity changes seen by 
Kumar et al. [133] and Zhou et al. [132] and demonstrated strong spatial 
agreement with LGE (Figure 2.2). In addition, patterns of heightened ΔS/So in 
patients with acute-MI mirrored T2-mapping (Figure 2.3), which is widely used to 
identify edema [117,118]. Our results further agreed with Weber et al. [131] who 
demonstrated altered MT-ratio in patients with sub-acute MI by acquiring pairs of 
bSSFP images with different MT-weighting. In the study by Weber et al. MT-
contrast was generated by altering the duration of the RF excitation pulse and 
the repetition time between cardiac phases causing reduced MT-ratio in 
edematous tissue in comparison to healthy tissue. However, elongation of the 
excitation pulse meant that differences in cardiac phase were present in images 
 35 
 
used to calculate the MT ratio. We chose to change the excitation flip angle, and 
not duration, in order to have a consistent cardiac phase between MT-weighted 
and proton density weighted images. Subsequently, our measure of ΔS/So is 
heightened in tissues that would enhance with LGE.  
 Identification of focal fibrosis with LGE is the established clinical standard 
and in our study heightened ΔS/So occurred in tissues identified by LGE as 
replacement (Figure 2.4) and reactive fibrosis (Figure 2.5). Emerging techniques 
to image diffuse fibrosis including mapping of post-contrast T1-relaxation times 
and measurement of GPC or ECV [77,114] have been correlated to collagen 
volume fraction at biopsy [134] and demonstrated predictive value for clinically 
relevant outcomes [115,135,136]. In our study we did not have access to 
hematocrit, however GPC values measured in non-enhanced myocardium 
agreed with prior studies of healthy tissue [126,137,138] and were significantly 
elevated in regions of interest identified by LGE (Figure 2.6). Comparing ΔS/So to 
GPC revealed a strong and promising association (Figure 2.7). However, 
detection of diffuse fibrosis with 2-point bSSFP requires further study with a 
larger sample and a consistent phenotype such as hypertrophic cardiomyopathy.  
In order to further examine the impact of changes in T1 relaxation times 
on the steady state signal intensity, a series of simulations of the steady state 
magnetization using the closed form equation for cine bSSFP were performed in 
Matlab (Figure 2.11). For all simulations we assumed that proton density is 1. 
Since bSSFP images are weighted by √T2/T1, increased T1 relaxation times in 
fibrotic scar tissue will have the opposite effect of decreased MT on the steady 
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state signal in the high flip angle acquisition (Figure 2.11). While this may be 
partially mitigated by concomitant increases in T2 relaxation times (Figure 2.11), 
the balance between increased T1 and reduced MT, and the potential limits this 
imposes upon detection via measurement of ΔS/So, requires additional 
examination in a large cohort of patients with chronic MI. In addition, given the 
contributions of MT, T1, and T2 to ΔS/So, it is unclear whether measurement of 
specific ΔS/So values can be used to differentiate edema from fibrosis. Additional 
studies with larger cohorts of acute and chronic MI patients are necessary to 
examine this possibility.  
 Mapping of native myocardial T1-relaxation times is emerging as a highly 
promising method for gadolinium free imaging of fibrosis [122,124,126]. Recently, 
several studies demonstrated increased T1-relaxation times in patients with 
edema [139], aortic stenosis [119], myocarditis [120], and hypertrophic and non-
ischemic dilated cardiomyopathies [121]. Native T1-relaxation times measured in 
our study using a MOLLI acquisition scheme at 1.5T were comparable to those 
measured under similar settings [125,140] and were significantly elevated in 
enhanced myocardium (Figure 2.6). While we observed a strong association 
between heightened native-T1and GPC, our association was weaker than 
observed in prior studies [120,121]. One likely factor contributing to this 
difference is that unlike most prior studies that focused on patient cohorts with a 
specific and profound phenotype, we sampled patients with a range of 
cardiomyopathies and varying degrees of edema or fibrosis. Also, artifacts 
introduced by motion correction [128] have led many prior studies to restrict data 
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analysis to the interventricular septum [119,121,130]. We analyzed myocardium 
across an entire short-axis slice, defining regions of interest based on LGE 
patterns. Results from a recent multi-center T1 mapping study demonstrated 
considerable regional variability in segmental native-T1 values at 1.5T [126]. 
Thus, our results likely reflect the influence of both motion correction artifacts on 
T1-estimation and regional T1 heterogeneity of healthy tissue that were not 
included in prior studies. Additionally, our scanner was equipped only with a 
MOLLI acquisition scheme that has demonstrated sensitivity to MT-effects [123], 
and thus the sensitivity of native T1-mapping may have improved with other 
mapping methods now available [125], including recently developed arrhythmia 
insensitive T1 mapping protocols [127].  
Images acquired with an excitation flip angle of 5° demonstrate low signal 
to noise, potentially leading to artificially elevated measurement of ΔS/So. We 
sought to limit the effect of random noise by averaging over three identical end 
diastolic phases and applying a median filtering algorithm to reconstructed maps. 
However, subjective assessment of ΔS/So maps by two blinded expert readers 
resulted in the incorrect interpretation of diffuse enhancement in ΔS/So maps in 
all but one of the false positive cases (Figure 2.9). We chose to use a 5° 
excitation flip angle in order to maximize the potential difference in MT-weighting 
between images, however, the acquisition of such images with slightly higher flip 
angles may present a more promising route to maintaining MT-contrast between 
image pairs while reducing the presence of voxels with spuriously high ΔS/So 
values. Alternatively, future studies could examine MT-weighting without the use 
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of low flip angle acquisitions via various magnetization preparation schemes that 
encode greater MT-weighting directly into the steady state magnetization. In 
addition, subjective analysis of ΔS/So maps by expert readers revealed a 
propensity to misidentify small sub-endocardial enhancement patterns as blood 
instead of enhanced tissue (Figure 2.10). In future studies, the use of blood 
signal suppression should be investigated as a mechanism to mitigate fall 
negative interpretation of ΔS/So maps.  
 A limitation to our study was that due to time constraints we acquired data 
in only one slice per patient without prior knowledge of disease status. In several 
patients, the slice chosen for our study did not demonstrate LGE-enhancement 
(Group II), however LGE-enhancement was present in other slices. Additionally, 
limitations on T1 and T2-mapping protocols on our scanner resulted in 
acquisition of bSSFP images at slightly higher spatial resolution. Consequently, 
partial volume error is more likely to influence T2 maps, and to a lesser extent T1 
maps, than 2-point bSSFP results. Care was taken to adjust boundaries to 
exclude border pixels affected by partial volume artifacts, however registration of 
pre and post gadolinium maps was not performed. The sensitivity to B1 
inhomogeneity remains a significant concern in cine bSSFP, particularly at higher 
flip angles. We simulated the bSSFP signal using a range of myocardial 
relaxation times and excitation flip angles. Based on the results of our simulation 
(Figure 2.11), and prior evidence that MT is maximal and constant above 
excitation flip angles of 30° [131], we chose to use a 45° flip angle in order to 
minimize the potential effects of B1-inhomogeneity. Also, changes in through-
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plane motion can modulate steady state behavior in the myocardium. For this 
reason we chose to focus our analysis on end-diastolic cardiac phases. In 
addition, the acquisition of two separate end expiratory breath-held scans 
increases the potential for misalignment between scans. Measurement of the 
DICE similarity coefficient between image pairs in our study was high, however 
we benefited from placement of our scans at the end of the non-contrast CMR 
workup, thus reducing potential misalignment that could occur if such scans were 
performed at the initiation of the CMR examination. Importantly, while registration 
algorithms can be used to compensate as they are in T1 mapping protocols, 
simple image intensity based algorithms would not be effective for registration of 
images acquired with a 5° excitation flip angle. 
 2-point bSSFP utilizes endogenous contrast mechanisms for gadolinium 
free CMR imaging. In this study, we demonstrated across a range of patients 
strong association between 2-point bSSFP and standard of care LGE-CMR. 
Importantly, since MT-contrast is an endogenous mechanism, the sensitivity to 
changes in MT-weighting increases with spatial resolution. In addition, MT-
contrast can be further increased with MT-preparation schemes not used in this 
initial study. In contrast, differences in native-T1 between healthy and diseased 
tissue cannot be further increased without increasing the magnetic field strength. 
With further development, MT-weighted CMR could potentially enable diagnostic 
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Demographics     
 Age (yrs) 51.74 ± 4.7 47.7± 16.5 51.39 ± 15.4 .406 
 BMI (kg/m2) 23.32 ± 1.5 29.3 ± 6.7 27.4 ± 3.6 .007 
 Female 4 (50.0) 8 (33.3) 4 (17.4) .315 
 White 7 (40.0) 20 (83.3) 18 (78.3) .815 
 African American  0  3 (12.5) 3 (13.0) 1.00 
 Hispanic or Other Race 1 (10.0) 1 (4.2) 2 (8.7) .051 
CMR Indication     
 Cardiomyopathy  7  (29.2) 10  (43.5) .371 
 Hypertrophic Cardiomyopathy  2  (8.3) 1 (4.3) 1.000 
 Pericarditis, Myocarditis  2  (8.3) 2  (8.7) 1.000 
 Sarcoidosis  2  (8.3) 2  (8.7) 1.000 
 Syncope  4  (16.7) 0  .109 
 Viability  3  (12.5) 5  (21.1) .461 
 Other  4  (16.7) 3  (17.4) 1.000 
Diagnosis     
 Ischemic Cardiomyopathy  4  (16.7) 10  (43.5) .060 
 Non-Ischemic Cardiomyopathy  10  (41.7) 7  (30.4) .547 
   Cardiomyopathy  0 2  (8.7) .234 
 No Evidence of Cardiomyopathy  8  (33.3)  0  .416 
 Other  2  (8.3) 4  (17.4) .416 
Ejection Fraction (%)  50.13 ± 14.4 42.57 ± 14.6 .081 
End Diastolic Volume (mL)  190.6  ± 76.0 217.65 ± 81.1 .244 
CVD without Enhancement: Patients referred for CMR not demonstrating LGE enhancement in 
imaged slice. CVD with Enhancement: Patients referred for CMR demonstrating LGE 





Figure 2.1. 2-pt bSSFP Imaging Method. 
 (A-C) Representative data from a healthy control. End-diastolic reference 
bSSFP images acquired with (A) 45° and (B) 5° flip angles provide MT-weighted 
and proton density reference images, respectively. (C) Maps of ΔS/So that are 
calculated from A and B demonstrate uniform and low values throughout the 
heart. (D-F) Representative data from a patient without LGE-enhancement. End-
diastolic reference bSSFP images acquired with (D) 45° and (E) 5° flip angles. 
This patient demonstrated no myocardial enhancement at LGE. (F) Map of ΔS/So 
demonstrates uniformly low values similar to the healthy control. For all maps, 
the color scale was chosen to emulate LGE imaging, with areas of 






Figure 2.2. Identification of edema and necrosis in a patient with acute 
myocardial infarction.  (A) End-diastolic reference image of a midventricular 
slice in which 2-point bSSFP, native T1-mapping, and LGE data were acquired. 
(B) LGE imaging reveals an area of hyper-enhancement along the septum 
indicative of edema and/or necrosis (red arrow). The corresponding maps of (C) 
ΔS/So, and (D) native-T1 both demonstrate similar spatial patterns of elevated 
values to LGE (red arrow). The corresponding T2-map and windowed bSSFP 
image can be found in Figure 2.3. 
 




Figure 2.3. T2-Mapping and Weighting in Acute MI. (A) Anatomical reference 
image from same patient as shown in Figure 2.2, with (B) corresponding LGE 
image demonstrating area of edema following acute MI (red arrow). (C) T2-
mapping revealed focally and significantly elevated T2 in the area of acute MI, 
corresponding to edema. (D). Significant contrast manipulation through window 
and leveling of (A) reveals similar enhancement in the area of edema (red arrow), 





Figure 2.4. Identification of scar tissue in chronic myocardial infarction. (A) 
Magnitude reconstructed bSSFP image reveals a thinned wall along the inferior 
right ventricular insertion point (red arrow). (B) LGE imaging confirms the 
presence of primarily sub-endocardial scar tissue as an area of signal 
enhancement (red arrow). Mapping of (C) ΔS/So and (D) native-T1 both reveal 
increased values within the scar tissue (red arrows), and normal values 






Figure 2.5. Two patients with non-ischemic dilated cardiomyopathy.  (A, E) 
Dilation of the left ventricle is present in both patients on end-diastolic images. In 
the first patient, (B) no LGE-enhancement is present, (C) ΔS/So is normal 
throughout the heart as is (D) native-T1. In the second patient, (F) mid-wall 
septal LGE-enhancement is present (red arrows). (G) Heightened ΔS/So is 
observed in close agreement with the LGE image (red arrows), however (H) 








Figure 2.6. Tissue characterization parameters. (A) ΔS/So was significantly 
elevated in tissue regions that enhanced on LGE images (Group IV) compared to 
non-enhanced regions from the same patients (Group III), patients without any 
LGE enhancement (Group II), and healthy controls (Group I). Similarly, (B) 
native-T1 and (C) native-T2 were significantly elevated in tissue that enhanced 
on LGE images compared to all other groups. (D) GPC was significantly higher in 
tissue that enhanced on LGE images compared to non-enhanced tissue regions 






Figure 2.7. Association of tissue characterization parameters with GPC. (A) 
ΔS/So (R = 0.82), (B) native-T1 (R = 0.55), and (C) T2 (R = 0.75) all associated 
strongly with GPC. Data points are shown for all measurements as either 







Figure 2.8. Association of enhanced area and transmurality between 2-
point bSSFP and LGE.  (A) Comparison of the enhanced myocardial area 
(represented as percent of total myocardial area) using 2-pt bSSFP and LGE 
revealed a strong association between the two methods (R2 = 0.84) with a slight 
bias towards larger areas of enhancement with 2-point bSSFP. (B) Bland-Altman 
plot comparing the difference between enhanced areas by both methods to the 
mean between both methods revealed a coefficient of covariance of 0.204. (C) 
Similarly, the comparison of the transmurality of enhancement by each method 
revealed a strong association between 2-point bSSFP and LGE (R2 = 0.73) with 





Figure 2.9. False positive identification of enhancement at ΔS/So.  (A-C) 
Scattered noise on ΔS/So maps led to the false identification of diffuse 
enhancement in 3 of the 4 false positive cases. A representative example of a 
patient without enhancement at LGE (A) that was classified by blinded readers 
as demonstrating diffuse enhancement at ΔS/So (B) in the septum with 
corresponding anatomical reference image (C).  (D-F) In one patient without 
enhancement at LGE (D), focal enhancement (arrow) was identified on the 






Figure 2.10. False negative identification at ΔS/So.  All cases in which blinded 
readers identified individuals with enhancement at LGE as normal at ΔS/So 
occurred in cases of sub-endocardial enhancement. (A) Representative LGE 
image from a patient with 50-75% sub-endocardial intermediate signal 
enhancement (red arrows) in the inferior wall. (B) The corresponding map of 
ΔS/So demonstrates elevated values in the same region (red arrows). (C) The 
corresponding anatomical reference image confirms that the elevated ΔS/So 






Figure 2.11. Simulations of changes in steady state signal intensity as a 
function of T1, T2, and flip angle. (A) Using a T2 relaxation time of 48ms (the 
mean amongst our healthy control cohort), and the TR and TE values from our 
scanning protocol, simulations confirm that lengthening of T1 relaxation times 
leads to a reduction in the steady state signal over a physiologically relevant 
range of T1 relaxation times. (B) However, changes in T1 relaxation times in 
fibrotic tissue are often accompanied by changes in T2 relaxation times that can 
have the opposite effect on the steady state signal. For further simulation of the 
steady state signal across a range of flip angles we examined healthy values 
(blue) using the mean T1 (1022.2 ± 48.2 (ms)) and T2 (48.2 ± 2.3 (ms)) 
relaxation times from our healthy cohort and previously mentioned TR/TE and 
proton density values. Separately, we simulated fibrotic tissue (red) using the 
mean T1 and T2 relaxation times from tissues that enhanced at LGE in patients 
that did not have acute-MI. This population included those with chronic MI and 
patients with enhancement determined by our cardiologist to be non-ischemic in 
origin. In this subset of patients (n = 12), the mean native-T1 relaxation time was 
1125.6 ± 136.5 (ms), and the mean T2-relaxation time was 52.2 ± 7.7 (ms). 
Examination of panel B demonstrates that decreases in steady state 
magnetization due to increased T1 are partially mitigated by increased T2 in 
fibrotic tissues. (C) The difference in steady state signal between the two 
populations suggests that the contrast observed in maps of ΔS/So is likely heavily 
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CHAPTER 3: MAGNETIZATION TRANSFER MAGNETIC RESONANCE 
IMAGING IDENTIFIES CARDIAC FIBROSIS IN END STAGE RENAL DISEASE 




Background: Patients with end stage renal disease (ESRD) suffer high rates of 
cardiac mortality, likely from pervasive development of fibrosis. The 
contraindication to gadolinium contrast agents prevents the use of late 
gadolinium enhancement cardiac MRI (CMR) for fibrosis detection in ESRD, 
although it is the clinical standard for cardiac tissue characterization. Measures of 
hypertrophy or reduced strain are widely used as surrogates for fibrotic burden, 
but are not specific to the development of fibrosis. We utilized our established 
magnetization transfer-weighted technique, 2-point balanced steady state free 
precession (2-pt bSSFP) for fibrosis identification and comparison with structure, 
function, and biomarkers in patients with ESRD. 
 
Methods: Patients on routine hemodialysis for ESRD (n=29) and healthy 
controls (n=33) were imaged on a 1.5 T MRI using the 2-pt bSSFP CMR 
technique. Myocardial ΔS/So was calculated as ΔS/So=(S5 – S45)/S5 *100 (%) 
where Si is the signal intensity per flip angle i. Strain and strain rates were 
measured in circumferential and longitudinal directions with a custom feature 
tacking algorithm. A standard healthy distribution of ΔS/So signal was generated 
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as a cumulative distribution function. The cumulative distribution of ΔS/So for 
each participant was compared to the healthy standard. The difference between 
cumulative distributions was integrated across the range of ΔS/So and the 
resulting divergence value was used as a quantitative marker of fibrosis. Pearson 
correlations were used to compare divergence to other widely used correlates of 
fibrosis and blood biomarkers. 
 
Results: Patients with ESRD were hypertrophic but with only slightly reduced 
longitudinal strain compared to healthy controls. Mean ΔS/So and divergence 
were elevated in patients with ESRD (144.7 ± 17.1% and 16.3 ± 14.3 AU 
respectively) compared to controls (129.9 ± 12.0% and 6.5 ± 5.7 AU, p<0.01 for 
both comparisons). Divergence was only moderately correlated with left 
ventricular mass index (LVMI; rho=0.31, p<0.05) but did not correlate with strain 
measures. Troponin T (TnT), fibroblast growth factor 23 (FGF23), and tissue 
inhibitor of metalloproteinase (TIMP) 1 and 2 were elevated in the ESRD group 
compared to controls. All of these biomarkers correlated with divergence, but 
FGF23 and TnT also correlated with LVMI indicating that these biomarkers are 
not specific enough to measure fibrosis alone. TIMP1 and 2 did not correlate with 
hypertrophy or strain, suggesting that these matrix remodeling proteins may be 
suitable for specific identification of fibrosis and may possibly serve as molecular 




Conclusions: 2-pt bSSFP CMR in patients with ESRD revealed that solely using 
hypertrophy or reduced mechanics as surrogate markers of fibrosis is 
inappropriate. While biomarkers of ischemia (TnT) and remodeling (FGF23) 
associated strongly with hypertrophy, they may lack specificity to cardiac fibrosis. 
TIMPs may emerge as both a biomarker of extracellular remodeling and potential 




 Sudden cardiac death is a leading cause of death for patients who are on 
routine hemodialysis for treatment of end stage renal disease (ESRD) [42]. 
Cardiac remodeling, which often manifests as hypertrophy in ESRD patients 
[47,51], and/or the development of replacement or reactive fibrosis [58,59] can 
lead to adverse cardiac events such as arrhythmia, heart failure, and eventually 
death. ESRD hemodialysis patients are contraindicated to gadolinium contrast 
agents [83], which are typically used for tissue characterization and fibrosis 
imaging with cardiac magnetic resonance imaging (CMR). Subsequently, since 
fibrosis and hypertrophy often occur in parallel, measurement of hypertrophy is 
widely used as a surrogate for fibrosis. In other studies, specific blood 
biomarkers including troponin T (TnT), fibroblast growth factor 23 (FGF23), and 
parathyroid hormone (PTH), whose levels correlate well with the degree of 
hypertrophy [141,142] are used as plasma biomarkers of fibrosis. Matrix 
metalloproteinases (MMP) and tissue inhibitor of MMP (TIMP) are under 
investigation as fibrosis specific markers in cardiomyopathy [143], heart failure 
[36,144] and cardiorenal syndrome [145-148]. Measures of reduced diastolic 
strain rate and global longitudinal strain (GLS) indicate stiffening of the left 
ventricle (LV) in kidney disease patients [60], but may only be sensitive after 
advanced fibrotic development. The currently employed surrogates of fibrosis—
hypertrophy, contractile function, and plasma biomarkers—are all indirect 
measures and may not be directly correlated with the development of fibrosis as 
a specific disease process in all patients with ESRD. Thus detecting cardiac 
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fibrosis and linking it with measureable biomarkers in the ESRD population 
remains both a challenge and a significant obstacle to the design and evaluation 
of potential lifesaving therapies. Since fibrosis occurs simultaneously with the 
expansion of interstitial space, two point balanced steady state free precession 
(2-pt bSSFP) CMR, which is described in Chapter 2, is uniquely suited to 
overcome the existing obstacles of studying cardiac fibrosis in patients with 
ESRD. 
 In this study, we used 2-point bSSFP CMR in healthy controls and 
patients with ESRD on routine hemodialysis for myocardial tissue 
characterization. We then correlated measures of fibrosis with cardiac mechanics 
and blood plasma biomarkers of remodeling that are purported to reflect 
underlying fibrotic burden. We hypothesized that the magnitude of fibrosis will 
correlate more strongly with the levels of markers of matrix turnover (MMPs and 
TIMPs) than with the magnitude of hypertrophy, reduced strain, or levels of non-
specific biomarkers TnT and FGF23. 
 
Materials and Methods 
Participants and Recruitment 
Patients on routine hemodialysis for ESRD were referred from the 
University of Kentucky Nephrology Department and healthy volunteers were 
recruited with assistance from the University of Kentucky Center for Clinical and 
Translational Science and academic departments. All participants were 
prospectively enrolled. Exclusion criteria included arrhythmia, inability to hold 
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one’s breath, and standard MRI safety and compatibility concerns. Additional 
exclusions for healthy volunteers were known cardiovascular disease, 
hypertension, diabetes, obesity, and tobacco use. A total of 31 patients with 
ESRD and 44 healthy controls were enrolled. Participants were excluded from 
data analysis due to the inability to adequately hold their breath or complete the 
MRI protocol (1 ESRD each) or for image quality concerns due to hardware 
issues (5 healthy controls). BMI > 26 (n=4), abnormal ECG (n=1) or discovery of 
aging related (n=1) or congenital abnormalities (n=1) in healthy controls were 
additional grounds for exclusion in data analysis. The research protocol was 
approved by the University of Kentucky Institutional Review Board and all 
participants gave voluntary informed consent prior to participation.  
 
Cardiac MRI Protocol 
A 12 lead electrocardiogram (ECG) was conducted prior to the MRI to 
detect arrhythmia or other electrical abnormalities. Participants were imaged on a 
1.5T Siemens Aera scanner (Siemens Healthcare, Erlangen, Germany) using an 
18 channel body coil and 12 channel chest coil and prospective ECG triggering. 
A 4-chamber long axis cine image was acquired during localizers for assessment 
of longitudinal strain. The 2-pt bSSFP method was completed as previously 
described (Chapter 2). During end expiratory breath holds, cine bSSFP image 
pairs were obtained at flip angles of 5° and 45° in a short axis stack, spanning 
the LV from mitral valve to apex. Additional scanning parameters include TE: 1.2 
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ms, TR: 3.2 ms, bandwith: 930 Hz, in plane spatial resolution: 1.02 x 1.02 mm, 
slice thickness: 8 mm, GRAPPA 2.  
 
Structure and Function Analysis 
Left ventricular volumes and mass were analyzed using short axis images 
in Argus Viewer (Siemens Healthcare, Erlangen, Germany). Left ventricular mass 
index (LVMI) was calculated as mass at end diastole (g) indexed to body surface 
area (m2). To characterize hypertrophy, H/R ratio was calculated at end diastole 
in a mid-ventricular slice as H/R= septal thickness / ventricular radius (cm) similar 
to Grossman, et al. [149]. Blood pressure data were collected post hoc from 
electronic medical records, when available. 
 
Strain Analysis 
Circumferential and longitudinal strain and strain rates were assessed 
using a custom feature tracking algorithm [150]. Endocardial borders were 
manually defined and automatically segmented into 6 sectors (Figure 3.1). 
Sectors were followed through the cardiac cycle using feature tracking and 
manually corrected for errors in border definition. Peak strain was defined as the 
maximum circumferential or longitudinal shortening from end diastole (%). 
Circumferential strain was averaged across all short axis slices. Global 
longitudinal strain was averaged across all endocardial sectors in 1 long axis 
view. In each slice, average shortening across all sectors was plotted as a 
function of the cardiac cycle. Systolic and diastolic strain rates were then defined 
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as the minimum and maximum slopes during contraction and relaxation, 
respectively (Figure 3.1).  
 
Image Analysis 
Offline image processing was conducted offline using MATLAB version 
2014a (The MathWorks Inc., Natick, MA). Cine image pairs acquired at 5° (not 
shown) and 45° (Figure 3.2 A and D) were assessed for misalignment and 
manually adjusted to realign the left ventricular myocardium when necessary. 2-
pt bSSFP data was analyzed as previously described (Chapter 2). Maps of ΔS/So 
(Figure 3.2 B and E) were generated for each slice location and each cardiac 
phase using the formula ΔS/So=(S45-S5)/S5 x 100 (%), where Si is the signal 
intensity per voxel at each flip angle i. To reduce random noise, 1 to 3 diastolic 
ΔS/So maps without cardiac motion were averaged together when calculating 
ΔS/So. The myocardium was manually defined on ΔS/So maps. Care was taken 
to exclude voxels with partial volume averaging from blood pool and pericardial 
fat. ΔS/So maps were automatically segmented into 6 sectors to calculate mean 
values per sector. Bullseye plots are used to demonstrate mean ΔS/So per sector 
across slices (Figure 3.2 C and F). Sectors are presented circumferentially, with 
slices extending radially from apex (center) to base (exterior). Quantitative 
analysis was completed using unfiltered ΔS/So maps. Figures are presented 





Quantification of Fibrosis 
A standard distribution was defined by combining all myocardial ΔS/So 
voxel values for all healthy participants in our study. To account for variations in 
heart size, the standard distribution was dynamically resized to match the 
number of voxels in each individual heart. For each participant, a cumulative 
distribution function of ΔS/So values was compared against the appropriately-
sized simulated distribution. A rightward shift in the distribution function occurs 
when a greater proportion of voxels demonstrate increased ΔS/So values 
consistent with tissue fibrosis. The difference between cumulative distributions 
was integrated across the range of ΔS/So and the resulting value was used as a 
quantitative marker of fibrosis termed divergence. An example of this analysis is 
presented in Figure 3.2 G. Cumulative distribution analysis was limited to voxels 
with 0-400% ΔS/So values to reduce the influence of potential region of interest 
errors or additional random noise. These ranges span the expected values for 
healthy, edematous, and fibrotic myocardium. 
 
Blood Biomarker Analysis 
In a subset of participants, blood samples were collected by standard 
venipuncture and allowed to clot at least 30 minutes. Samples were centrifuged 
at 1300g for 10 minutes at 4°C and stored at -80°C until analyzed with 
commercially available assay kits. Serum concentrations of TnT were analyzed 
by quantitative electrochemiluminescent immunoassay by ARUP Laboratories 
(0098803, Salt Lake City, UT, USA). MMP2 and MMP9 were measured by 
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enzyme-linked immunosorbent assay (ELH-MMP2, ELH-MMP9 ELISA; Ray 
Biotech, Norcross, GA, USA). FGF23, PTH, TIMP1 and TIMP2 were analyzed by 
Milliplex® magnetic bead panels (HBNMAG-51K, HTMP2MAG-54K; EMD 
Millipore, Billerica, MA). Assays were run in duplicate and averages were used 
for all analyses.  
 
Statistical Analysis 
Statistical results were computed using IBM SPSS Statistics Version 22 
(IBM Corp, Armonk, NY). Shapiro-Wilk and Levene’s tests were used to assess 
the normality and homogeneity of variance for all variables. Student’s t test or 
Mann Whitney U tests were used where appropriate. Spearman correlations 
were used to compare blood biomarkers against imaging results. Continuous 
variables are presented as mean ± standard deviation or median [interquartile 
range], where appropriate. Categorical variables are presented as count (%). 
P<0.05 was considered significant for all tests.  
 
Results 
Twenty nine patients with ESRD and 33 healthy controls were included in 
the study. Demographic characteristics are detailed in Table 3.1. Groups were 
well matched in age and gender. Patients with ESRD had larger body mass 
index compared to controls (<0.001). Hemodialysis vintage in patients with ESRD 
was 4.8 ± 3.2 years. Six patients had prior kidney transplants that subsequently 
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failed, requiring continuation of hemodialysis. Additional clinical features of the 
ESRD group are described in Table 3.2.  
 
Clinical Measures of Structure, Function, and Strain 
Clinical measures from ECG and CMR are listed in Table 3.1. QRS 
complex duration was similar between patients with ESRD and controls 
(p=0.694), although 3 patients with ESRD had QRS duration longer than 120ms. 
Corrected QT interval (QTc, normalized to 60 beats per minute) was longer in 
patients with ESRD than controls (p<0.001). QTc was greater than 440ms in 18 
patients with ESRD but only 6 healthy controls. The majority of patients with 
ESRD had preserved ejection fraction with no differences between groups, 
although 6 patients had EF below 55%. Mean LV mass was 112.5 ± 31.8g in 
controls and 189.0 ± 65.1g in patients with ESRD (p<0.001). LVMI, septal 
thickness, and H/R ratio were elevated in patients with ESRD compared to 
controls (p<0.01 for all, see Table 3.1). There were no differences in strain 
measurements between the ESRD and healthy control groups for circumferential 
peak strain, systolic, or diastolic strain rates (Figure 3.3 A-C). Longitudinal peak 
strain was slightly reduced in patients with ESRD (Figure 3.3 D) but did not reach 
statistical significance. Longitudinal systolic and diastolic strain rates were similar 






Tissue Characterization by 2-pt bSSFP 
Representative ΔS/So maps from a healthy control (Figure 3.4) depict the 
uniformly low ΔS/So values typical of healthy myocardium. An example patient 
with ESRD is presented in Figure 3.5. This patient demonstrates diffuse 
enhancements in ΔS/So, particularly towards the base of the LV. Importantly, if 
this patient were to undergo myocardial tissue biopsy, the historical gold 
standard for fibrosis detection where a small tissue sample is extracted from the 
epicardial surface of the left ventricular septum at the mid-ventricle, the chance of 
a false negative result would be high. The longitudinal position of the tissue 
samples would impact the extrapolated whole-ventricle estimation of fibrotic 
burden, which is actually highly varied across slices. Similar to Schietinger et al. 
[59], we also found examples of 3 distinct patterns of fibrosis in patients with 
ESRD (Figure 3.6), associated with both ischemic and non-ischemic origins. 
From the ΔS/So maps generated at each short axis slice position, mean global 
ΔS/So was calculated across the LV myocardium. Patients with ESRD had 
significant elevation in global ΔS/So (144.7 ± 17.1%) compared to controls (129.9 
± 12.0%, p<0.001, Figure 3.7 A). Divergence was also significantly increased in 
the ESRD group (9.8 AU [6.0, 23.6]) compared to controls (4.7 A.U. [1.2, 11.5], 
p=0.003, Figure 3.7 B), indicating a greater fibrotic burden in these patients. 
 
Structure and Function Alterations are not Synonymous with Fibrosis 
Representative examples of LV hypertrophy in the ESRD group are shown 
in the anatomical cine images (α=45°) in Figure 3.8 A-D. While each of these 
 65 
 
example participants is considered hypertrophic, there is a wide range of fibrosis 
patterns, indicated by elevated signal on corresponding ΔS/So maps (Figure 3.8 
E-H). Spearman correlations were used to investigate the association of fibrosis 
with hypertrophy, circumferential diastolic strain rate, and global longitudinal 
strain (Figure 3.9). Moderate correlations were evident when comparing 
divergence with LVMI (rho=0.31, p=0.014) and septal thickness (rho=0.27, 
p=0.035), which are commonly utilized surrogate measures of fibrosis. No 
correlation was found comparing divergence with diastolic strain rate (rho=0.06, 
p=0.646) or global longitudinal strain (rho=0.02, p=0.910). LVMI correlated with 
diastolic strain rate (rho=-0.26, p=0.043) and global longitudinal strain 
(rho=0.383, p=0.002), indicating that increased hypertrophy was associated with 
worsening relaxation and contraction. In patients with ESRD, hemodialysis 
vintage was not correlated with divergence (rho=-0.164, p=0.395), indicating that 
length of time on hemodialysis is also not a good indicator of fibrotic burden. 
 
Blood Biomarkers and Correlations with LV Remodeling 
 We collected blood samples from a subset of healthy controls (n=25) and 
patients with ESRD (n=16). Serum concentrations of blood biomarkers are 
detailed in Table 3.3. The typical biomarkers of ischemia and cardiac remodeling, 
TnT and FGF23, were elevated in patients with ESRD (Figure 3.10 A-B), as was 
PTH. Markers of extracellular matrix turnover, TIMP1 and TIMP2 were also 
elevated in the ESRD group (Figure 3.10 C-D). Correlation analysis with 
divergence revealed moderate associations between fibrosis and TnT (rho=0.32, 
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p=0.043), PTH (rho=0.33, p=0.035), TIMP1 (rho=0.39, p=0.013), and TIMP2 
(rho=0.40, p=0.011) but not FGF23 (Figure 3.10 E-H). Interestingly, TnT 
(rho=0.59, p<0.001), FGF23 (rho=0.343, p=0.030), and PTH (rho=0.37, p=0.019) 
also correlated with LVMI while TIMP1 and 2 did not. These overlapping 
correlations reveal the complex interaction between hypertrophy and fibrosis, 
while indicating that TnT, FGF23, and PTH may not be suitable for fibrosis 
detection in patients with ESRD. 
 
Discussion 
Reactive and replacement patterns of fibrosis have been previously 
identified in patients with ESRD using gadolinium [58,59]. Due to the risk of 
nephrogenic systemic fibrosis [151], patients with ESRD are now excluded from 
MRI examinations with gadolinium. Without the availability of safe and 
noninvasive fibrosis measurement techniques, surrogate measures such as 
hypertrophy or reduced contractility are widely used to estimate fibrotic burden 
for diagnostic, prognostic, and treatment efficacy purposes. In this study, we 
utilized 2-pt bSSFP, a magnetization transfer contrast CMR technique, to 
characterize myocardial fibrosis without the need for gadolinium in patients on 
routine hemodialysis for ESRD. We used quantitative evidence of fibrosis to 
challenge the current prevailing view that using hypertrophy or reduced 
contractility are accurate surrogates for fibrosis measurements. 
ΔS/So values in healthy, age-equivalent controls agreed with our prior data 
using 2-pt bSSFP (Chapter 2, Figure 2.6). We demonstrated elevated myocardial 
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ΔS/So in patients with ESRD, corresponding to increased interstitial fibrosis and 
decreased magnetization transfer. Signal elevation is evident upon subjective 
inspection of ΔS/So maps (Figure 3.5, Figure 3.8) and with quantitative analysis 
of the distributions of ΔS/So (Figure 3.7). While greater than healthy tissue, mean 
ΔS/So values over the LV in patients with ESRD fell below focal values for tissue 
that enhanced at LGE from our previous study (Chapter 2). This is expected due 
to the propensity for a diffuse pathology in patients with ESRD.  
Our patients with ESRD demonstrated prolonged QTc with 18 patients exceeding 
the standard normal cutoff of 440ms. Lengthened QT times may be 
demonstrative of increased ventricular fibrosis which can slow conduction times 
[38]. Prolonged QT is associated with the development of ventricular arrhythmia, 
specifically torsades de pointes [152], and is associated with mortality and 
sudden cardiac death in patients hemodialysis [153,154]. In addition to fibrosis, 
severe alterations in electrolytes may predispose patients on hemodialysis to 
development of arrhythmia [49,154] and time since last treatment may impact 
ECG recordings [154]. These confound make the detection of fibrosis a complex 
task by ECG alone. 
Since fibrosis can lead to ventricular stiffening [35,36], strain 
measurements by echocardiography [165] and CMR [60] have been used to 
estimate fibrosis in patients with ESRD. However, the drastically fluctuating 
hemodynamics in patients receiving hemodialysis modify echocardiographic 
measures [52,68], which may not actually associate with histological measures of 
fibrosis in this population [51]. Strain measurements correlated with hypertrophy 
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but not fibrosis in this study, indicating that measures of ventricular stiffness may 
be a consequence of thickened LV walls and not specifically the development of 
fibrosis. 
Previous reports indicate a varied but large proportion—up to 91%[55]—of 
hemodialysis patients with hypertrophy [56-58]. Hypertrophy is associated with 
emergence of cardiovascular disease and death in the general population [17,18] 
and with poorer prognosis in patients with hypertension[155], aortic 
stenosis[156], heart failure with preserved ejection fraction [157], and ESRD [58]. 
Indeed, our findings confirmed that hypertrophy was prevalent among individuals 
with ESRD. However, using MRI strain imaging, which is more accurate and 
reproducible than comparable ultrasound based methods, we observed only 
slightly reduced longitudinal contraction compared to healthy, age-equivalent 
controls (Table 3.1,Figure 3.3). Though hypertrophy is prognostic, it does not 
differentiate the etiology of adverse cardiac outcomes such as development of 
interstitial fibrosis leading to fatal arrhythmias. As described in our study, 
hypertrophy only moderately associated with divergence (Figure 3.9) and may 
not be an appropriate surrogate to detect fibrosis or probe for biomarkers specific 
to fibrosis. In fact, others have shown a lack of correlation between hypertrophy 
and fibrosis in patients with kidney disease [60] and demonstrated that fibrosis is 
an independent risk factor for cardiovascular mortality in ESRD above and 
beyond hypertrophy or contractile dysfunction [51]. 
Investigations of molecular mechanisms of remodeling have identified 
FGF23 [141,158,159], PTH [142,159,160] and serum phosphates [158,159] as 
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potential factors driving ventricular hypertrophy. Specifically, FGF23 is correlated 
with LV hypertrophy [53,141] and linked to increased risk of cardiac mortality in 
patients with ESRD [141,142,158]. Emerging therapies seeking to abrogate 
effects of elevated serum FGF23 levels through dietary intervention [53,158,161], 
oral phosphorous binder therapy [53,158] or use of lanthanum carbonate [162], 
are promising for the reduction of serum FGF23 levels over time. However, prior 
studies have demonstrated that phosphate binder and vitamin D therapies 
[141,163], and even renal transplantation [164] fail to reverse left ventricular 
hypertrophy, despite improving outcomes [161]. FGF receptors that are normally 
only activated after myocardial infarction to promote formation of fibrotic scar 
tissue may be activated by excess FGF23 [53], suggesting that fibrotic 
remodeling may play a greater role in promoting adverse cardiac events in ESRD 
patients. This view is substantiated by extensive interstitial fibrosis measured by 
biopsy [51] and LGE CMR [58,59], prior to its contraindication in ESRD patients, 
along with the link for cardiac fibrosis to promote arrhythmia [62], heart failure, 
and sudden death. In fact, increased fibrotic burden is associated with worse 
prognosis and predicts sudden cardiac death independent of hypertension, 
diabetes, ejection fraction, LV dilation, and cardiomyocyte hypertrophy in patients 
with ESRD [51].  
Translational and early clinical trials show promise for the cardiac benefits 
of emerging therapies such as spironolactone [166,167], galectin 3 blockade 
[168], and FGF23 blockade [141,169] but with outcome measures of reduced 
hypertrophy, improved contraction, or decreased cardiac death. Cardiac fibrosis 
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has been attenuated in animal models of pressure overload hypertrophy treated 
with spironolactone [170] and dilated cardiomyopathy [171] and renal failure 
[172] treated with rapamycin. In patients with ESRD, the progress of these and 
other potentially lifesaving treatments is limited by the reliance on hypertrophy or 
reduced contraction for disease monitoring. While hypertrophy and fibrosis are 
interrelated, if patients are diagnosed and selected based only on hypertrophy or 
contractile status for clinical trials whose outcomes only measure improvements 
in structure or strain, the entire fibrotic disease process is overlooked. It is 
imperative for the design and development of targeted anti-fibrotic therapies to 
rely on the accurate detection of fibrosis and specific molecular mechanisms in 
the context of ESRD and hemodialysis, otherwise new therapeutics may 
effectively treat hypertrophy or contraction without affecting the independent 
development of fibrosis. 
The patients examined in this study demonstrated significantly elevated 
TnT, FGF23, PTH, TIMP1, and TIMP2, reduced MMP9 and a trend toward 
elevated MMP2 compared to healthy controls (Table 3.3). While each of these 
biomarkers may indicate generic risk of arrhythmia or cardiac death, there is a 
complex interaction between hypertrophy and fibrosis that is not distinguished by 
these biomarkers. In fact, we found correlations with both hypertrophy and 
fibrosis for TnT, FGF23 (Figure 3.10 E-F) and PTH, indicating that none of these 
are specific enough to detect fibrosis alone. 
MMPs play a crucial role in degrading the existing extracellular matrix, for 
example, in acute myocardial infarction to allow infiltration of inflammatory cells 
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to clear necrotic myocytes and initiate the healing process [173]. MMP2 and 9, 
which comprise the gelatinases, primarily degrade denatured collagen, but may 
also have a pro-fibrotic role in the heart [174]. TIMPs 1 and 2 are the most widely 
investigated inhibitors of MMPs. TIMPs bind the catalytic domain of MMPs in a 
1:1 fashion, thereby preventing degradation of MMP substrates [175]. 
Independent of MMP interactions, TIMPs have alternative signaling roles, which 
can result in increased cardiac fibroblast proliferation and activation, and 
therefore collagen synthesis [176]. The balance between MMP and TIMP ratio is 
crucial for maintaining proper extracellular matrix form and function. For these 
reasons, MMPs and TIMPs have been investigated as molecular mechanisms of 
cardiac remodeling and fibrosis, and the subsequent link with contractile 
dysfunction in non-diseased aging populations [22] as well as hypertrophic 
cardiomyopathy [143], overload induced hypertrophy [177], myocardial infarction 
[173,178], hypertension [179], and heart failure [144]. MMPs and/or TIMPs may 
not only serve as prognostic or diagnostic markers, but pharmaceutical targets 
for adverse structural or fibrotic remodeling. A promising study in a murine model 
of experimental myocardial infarction demonstrated the beneficial effects of 
inhibiting MMP2 and MMP9 by doxycycline, an FDA approved antibiotic [180]. 
MMPs and TIMPs have been investigated as cardiac biomarkers in 
hemodialysis patients, with conflicting results [146,148,181,182] but with the goal 
of being easily measured parameters for non-invasive myocardial tissue 
characterization [183]. We have shown that patients with ESRD not only 
demonstrate elevated circulating TIMP1 and TIMP2, but that both of these 
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biomarkers correlate with measures of fibrosis, independent of hypertrophy 
(Figure 3.10 G-H). Importantly, it has been shown that MMPs and TIMPs are 
elevated in patients with deteriorating heart failure, but not end stage heart failure 
or normal function [144]. Thus, MMPs and TIMPs may be important indicators of 
cardiac disease progression, possibly through development of fibrosis. Future 
investigations are warranted to understand cardiac remodeling processes, tissue 
characterization, and MMP/TIMP involvement in hemodialysis patients, while 
taking into account the effects of hemodialysis treatment on the circulating 
concentrations of biomarkers [147,148]. 
Efforts to image myocardial fibrosis without gadolinium are currently under 
investigation, with the goal of applying non-contrast CMR to patients with kidney 
failure or other contraindications to gadolinium. Mapping of native T1 relaxation 
times [88,89] has shown promise for tissue characterization in cardiomyopathy 
[95,97], aortic stenosis [94], and Anderson-Fabry disease [104]. Recently, native 
T1 mapping has been applied to patients with ESRD [90,99,184]. Graham-Brown 
et al. demonstrated globally elevated T1 times as well as diffuse and non-
ischemic, focal fibrosis patterns [184], similar to a previous report using LGE 
CMR [59] and to our results shown in Figure 3.6. The patients included in that 
study demonstrated reduced contractility, indicating that this sample may have 
had established heart failure and more advanced fibrosis compared to our 
patients, although the differences in T1 maps are visually subtle. Importantly, 
unless corrected for hematocrit, T1 times may be erroneously elevated due to 
anemia caused by hemodialysis and may vary depending on time since last 
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treatment. T1 mapping sequences are also commonly sensitive to elevated and 
variable heart rates, particularly for longer T1 times [91], which all routinely occur 
in individuals with ESRD.  
A few important limitations are relevant to this study. Since 2-pt bSSFP 
imaging requires 2 consecutive end-expiratory breath holds, patient motion and 
breath hold variation between acquisitions may limit this technique. We manually 
registered any misaligned image pairs to adjust for inaccurate position. While this 
could introduce additional human error and noise in the ΔS/So maps, many slices 
were salvaged for data analysis that would otherwise be excluded from this 
study. While we are currently unable to collect low and high MT-weighted images 
simultaneously in a single breath hold, future investigations will aim to reduce 
table time and patient fatigue, while optimizing MT-weighting sequences to 
reduce analytical limitations. 
Regions of interest were carefully defined to include only myocardial 
voxels, however it is possible that some voxels with partial volume effects from 
the blood pool or pericardial fat were included in our analyses. These erroneous 
voxels are more likely to be included for healthy controls since the myocardium is 
often thinner than in patients with ESRD. Thus, our calculation of ΔS/So may be 
slightly elevated in controls and true group differences may be greater than what 
we described. To eliminate the impact of this noise, in quantitative analysis we 
restricted the range of voxel values to 0-400% for ΔS/So which incorporates the 
expected physiologic ranges for normal and fibrotic myocardium. 
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In conclusion, we have shown that endogenous contrast mechanisms can 
be measured in the myocardium of patients with ESRD using 2-pt bSSFP CMR. 
MT-weighted CMR identifies increased fibrosis in patients with ESRD, which only 
moderately associated with hypertrophy but not systolic or diastolic dysfunction. 
The accuracy of imaging-guided biomarkers such as TIMP1 or 2 will benefit from 
the capacity to delineate between hypertrophy and fibrosis and may serve as 
potential therapeutic targets for future therapies to attenuate fibrosis in patients 
on hemodialysis for ESRD. Accurate and safe measurement of fibrotic burden 
and distribution could inform appropriate pharmaceutical interventions or serve 
as selection criteria for alternative treatments such as radiofrequency ablation 
and implantable cardioverter-defibrillator to prevent arrhythmias and ultimately 
reduce the risk of sudden cardiac death in patients with ESRD. We have 
challenged the dogmatic view that degree of hypertrophy or contractility directly 
represents fibrotic burden and have offered a non-contrast imaging solution to 
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Table 3.1. Participant Characteristics.
 Variable Healthy Controls  (n=33) 
Patients with ESRD  
(n=29) 
Demographics   
  Age (yrs.) 54.0 ± 10.9 53.7 ± 12.8 
  Male 15 (45) 14 (48) 
  White/Caucasian 29 (88) 16 (55) 
  Black/African American 1 (3) 12 (41) 
  Asian 0 1 (3) 
  American Indian 1 (3) 0 
  Hispanic 2 (6) 0 
  Body Mass Index (kg/m2) 24.2 ± 2.3 31.6 ± 6.8† 
Cardiac Structure and Function   
  Left Ventricular Mass Index (g/m2) 60.4 ± 13.3 94.3 ± 27.8† 
  Septal Thickness (cm) 0.9 ± 0.2 1.3 ± .03† 
  H/R Ratio 0.3 ± 0.1 0.5 ± 0.2† 
  End Systolic Volume (mL) 34.5 [25.3, 46.0] 36.5 [31.5,54.4] 
  End Diastolic Volume (mL) 92.3 ± 25.3 116.5 ± 41.0* 
  Ejection Fraction (%) 60.5 [56.0, 64.4] 63.8 [58.4, 68.1]  
  Heart Rate (bpm) 60.8 ± 8.8 72.3 ± 10.8† 
  QRS Duration (ms) 90.0 [84.0, 98.0]                                                                                                                                                                                                                                       94.0 [77.0, 104.0]
  QTc interval (ms) 422.7 ± 18.4 463.0 ± 37.7† 
Cardiac Mechanics   
  Global Diastolic Strain Rate (%/s) 174.1 ± 33.9 162.8 ± 41.7 
  Global Longitudinal Strain (%) -21.8 [-26.0, -20.1] -20.9 [-23.3, -18.7]* 
Continuous variables are presented as mean ± standard deviation or median 





Table 3.2. Clinical Features of Patients with ESRD.
Clinical Features Results 
Dialysis Duration (years) 4.8 ± 3.2 
Primary Etiology of End Stage Renal Disease  
  Diabetes 12 (41) 
  Hypertension 7 (24) 
  Glomerulonephritis 2 (7) 
  Reflux Nephropathy 2 (7) 
  Obstructive Nephropathy 1 (3) 
  Interstitial Nephritis 1 (3) 
  Focal Segmental Glomerulosclerosis 1 (3) 
  Unknown 3 (10) 
Comorbidities  
  Hypertension 27 (93) 
  Diabetes 17 (59) 
  Prior Myocardial Infarction 4 (14) 
Continuous variable is presented as mean ± standard deviation. 





Table 3.3. Blood Biomarker Results
 Variable Healthy Controls  (n=25) 
Patients with ESRD 
(n=16) 
p 
TnT (ng) undetected 0.05 [0.0, 0.18]  <0.001 
FGF23 (pg) 0.00 [0.00, 0.00] 521.22 [29.47, 1210.85] 0.001 
PTH (pg) 139.66 [78.45, 167.61] 544.20 [340.78, 901.96] <0.001 
MMP2 (ng) 11.21 [6.89, 20.08] 23.02 [11.88, 33.35] 0.051 
MMP9 (ng) 931.90 [643.31, 1201.70] 552.53 [347.87, 718.14] 0.026 
TIMP1 (pg)  4336.00 [4090.50, 5757.50] 6371.00 [4323.00, 7567.00] 0.005 
TIMP2 (pg) 3255.00 [2555.50, 4408.50] 4676.00 [2953.00, 5302.00] 0.035 
TnT: troponin T, FGF: fibroblast growth factor, PTH: parathyroid hormone, MMP: 
matrix metalloproteinase, TIMP: tissue inhibitor of MMP. Values are presented as 
median [interquartile range]. p< 0.05 was considered significant by analysis with 






Figure 3.1. Cardiac mechanics analysis in a healthy control.  (A) In each 
transverse slice, endocardial borders were manually defined at end diastole and 
automatically followed through the cardiac cycle using a feature tracking 
algorithm. (B) Average circumferential shortening across all sectors was plotted 
as a function of the cardiac cycle (grey lines), and diastolic strain rate was 
calculated as the maximum slope during relaxation (red line), which was 
120.32%/sec for this participant. (C) Similarly, longitudinal strain as a function of 
cardiac phase was calculated from a 4 chamber longitudinal cine image. (D) The 
peak global longitudinal strain was defined by the maximum shortening value 





Figure 3.2. Two-pt bSSFP technique and quantitative analysis.  (A) A cine 
bSSFP image at α=45° in a representative healthy control was paired with an 
image with α=5° (not shown). Maps of ΔS/So were generated as ΔS/So=(S45-
S5)/S5 x 100 (%), where Si is the signal intensity per voxel at each flip angle i. (B) 
A ΔS/So map from this healthy control demonstrates low and uniform ΔS/So 
values in a mid-ventricular slice. (C) Low ΔS/So is evident across all slices and 
sectors of the heart in a whole-heart bullseye plot representing mean ΔS/So per 
sector in this control. (D) A mid-ventricular image taken at α=45° from a 
representative patient with ESRD and (E) the corresponding ΔS/So map, with 
noticeable elevated signal intensity. (F) Elevated values are present throughout 
the ventricle, as seen in the bullseye plot. (G) Using all LV myocardial ΔS/So 
values from the control group, a simulated cumulative distribution function was 
generated (black). The simulation was dynamically resized to match the number 
of voxels per heart and compared to the cumulative distribution function of 
observed ΔS/So values for each individual ventricle. Cumulative distributions from 
the healthy control in b (orange) and patient with ESRD in e (red) are shown. We 
integrated the area between the simulation and each participant’s distribution 
(here, the patient from E) to define the divergence (gray) in ΔS/So. Divergence is 




Figure 3.3. Relaxation was preserved and contractility was slightly reduced 
in patients with ESRD. (A) Circumferential peak strain, (B) systolic strain rate, 
and (C) diastolic strain rate were similar between groups (all p>0.05). (D) Global 
longitudinal strain was slightly reduced in patients with ESRD (-20.5 ± 4.1%) 
compared to controls (-22.9 ± 3.5%, p=0.035), while (E) longitudinal systolic and 
(D) diastolic strain rates were not different (p>0.05 for both). A large overlap in 
values indicates that global longitudinal strain is not a robust, independent 





Figure 3.4. Representative images from a healthy control.  In a 
representative healthy control, ΔS/So maps from base (top left) to apex (bottom 
right) reveal uniformly low myocardial signal throughout the LV. Low ΔS/So is 




Figure 3.5. Representative images from a patient with ESRD and moderate 
fibrosis. ΔS/So maps from base (top left) to apex (bottom right) in an example 
patient with ESRD with moderate diffuse fibrosis. The LV was noticeably 
hypertrophied with scattered ΔS/So enhancement, indicating diffuse fibrosis, 
particularly in basal slices. This example demonstrates the need for accurate 
fibrosis mapping across the entire LV, since fibrosis burden and pattern changes 





Figure 3.6. Recapitulation of three prevailing patterns of fibrotic tissue in 
renal failure patients. Prior to the FDA warning and contraindication of 
gadolinium, Schietinger et al.[59] observed 3 dominant patterns of late 
gadolinium enhancement in renal failure patients: (A) thin scar like enhancement, 
(B) diffuse subendocardial fibrosis, and (C) focal fibrosis at the ventricular 
insertion points unrelated to ischemia. (A-C adapted from [59].) MT-weighted 
fibrosis in renal failure patients imaging reveals similar patterns to those seen 
previously using late gadolinium enhancement MRI. (D-F) End diastolic bSSFP 
images in 3 renal failure patients and corresponding maps of ΔS/So reveal (G) 
thin enhanced tissue , (H) diffuse enhancement, and (I) focal enhancement at the 




Figure 3.7. Patients with ESRD had increased signal intensity and fibrotic 
burden. (A) Whole-ventricle ΔS/So values were significantly elevated in patients 
with ESRD (144.7 ± 17.1%) compared to controls (129.9 ± 12.0%, p<0.001). (B) 
Divergence was increased in patients with ESRD (16.3 ± 14.3) compared to 
controls (6.5 ± 5.7 AU, p=0.003), indicating a greater fibrotic burden. Gray bars 






Figure 3.8. Patients with ESRD were hypertrophic but displayed a variety of 
fibrosis patterns. (A-D) Representative mid-ventricular images (α=45°) from 4 
individual patients with ESRD who displayed hypertrophy, particularly in the 
interventricular septum. (E-H) Corresponding ΔS/So maps from the patients in a-
d demonstrated a wide range of signal elevation in these patients, indicating that 






Figure 3.9. Fibrosis moderately associated with hypertrophy but did not 
correlate with strain. (A) Left ventricular mass index (LVMI) demonstrated a 
moderate correlation with divergence (rho=0.31, p=0.01). Notably, the correlation 
between LVMI and divergence was not linear. Patients with the highest values of 
either variable did not regularly demonstrate the highest values in the other. (B) 
Neither diastolic strain rate nor (C) global longitudinal strain correlated with 





Figure 3.10. Patients with ESRD had elevated blood biomarkers with 
moderate correlations to fibrosis.  Patients with ESRD demonstrated elevated 
concentrations of (A) troponin T (TnT), (B) fibroblast growth factor (FGF) 23, (C) 
tissue inhibitor of metalloproteinase (TIMP) 1 and (D) TIMP2. See Table 3.3 for 
complete biomarker results. (E) Spearman correlation analysis revealed a 
moderate association between divergence and TnT (rho=0.32, p=0.04). (F) 
FGF23 did not correlate with divergence (p=0.12). (G) TIMP1 and (H) TIMP2 
demonstrated a moderate correlation with divergence (rho=0.39, p=0.01 for 
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CHAPTER 4: LONGITUDINAL MONITORING OF CARDIAC FIBROSIS 
PROGRESSION USING MAGNETIZATION TRANSFER CARDIAC MRI IN 
PATIENTS ON HEMODIALYSIS FOR END STAGE RENAL DISEASE 
 
Synopsis 
Background: Chronic hemodialysis treatment is associated with a time-
dependent increased risk of cardiac mortality, up to 20 times greater than the 
general population. Ventricular fibrosis may be a leading cause of higher death 
rates, yet the exclusion from gadolinium enhancement cardiac MRI (CMR) 
excludes patients with end stage renal disease (ESRD) from noninvasive fibrosis 
identification. Progressive hypertrophy and ventricular stiffness are currently 
utilized as alternate measures of fibrotic burden but are more likely measures of 
structural and functional alterations irrespective of the development of fibrosis. 
We employed our non-contrast, 2 point balanced steady state free precession (2-
pt bSSFP) CMR technique to test the hypothesis that fibrosis progresses over 1 
year in patients with ESRD independent of any changes in hypertrophy or 
contractility. 
 
Methods: Patients on routine hemodialysis for treatment of ESRD who 
completed our previous study were invited to participate in a follow up 1 year 
later. ΔS/So and strain were calculated using our standard techniques. Using the 
healthy standard distribution of ΔS/So established in our prior study, we 
compared cumulative distributions of ΔS/So acquired in follow up scans to 
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calculate divergence, a metric of fibrotic burden. Measures of structure, function, 
and fibrosis were compared between the 2 time points with paired t tests. 
 
Results: Six patients completed follow up 2-pt bSSFP imaging. All patients were 
hypertrophic at baseline but demonstrated minimal alterations in hypertrophy 
over time. Changes in circumferential and longitudinal strain were varied, but not 
significantly altered from baseline. ΔS/So and divergence were considerably 
increased at follow up by an average of 10.3 ± 16.0% and 7.1 ± 13.7% AU, 
respectively.  
 
Conclusions: Patients with ESRD did not demonstrate significant changes in 
hypertrophy nor contractility over a 1 year follow up period. The phenotypes of 
fibrosis progression were varied, which demonstrates the heterogeneous 
development of fibrosis in this population and the need for fibrosis specific 
monitoring independent of structural and functional alterations. Non contrast 
fibrosis imaging may serve as a better prognostic tool than the current 
alternatives of hypertrophy and stiffness, aiding in more appropriate monitoring 




 One in 4 patients on hemodialysis for treatment of end stage renal disease 
(ESRD) will die from sudden cardiac death [44]. For long term hemodialysis 
patients (up to at least 6 years), risk of cardiovascular mortality is 10-20 times 
greater than the general population [47]. Over the last 30 years, post-mortem 
histological studies have repeatedly established high prevalence of cardiac 
fibrosis in deceased ESRD patients [55,58,59]. It is now appreciated that the 
progressive development of cardiac fibrosis is associated with increased risk of 
arrhythmia [69], heart failure [64], and sudden cardiac death in ESRD [51]. 
Cardiac fibrotic burden may be correlated with time on dialysis [55] while cardiac 
death rates increase steadily over multiple years of treatment [185]. 
Patients with ESRD are excluded from late gadolinium enhancement 
(LGE) cardiac magnetic resonance imaging (CMR) due to the risk of developing 
nephrogenic systemic fibrosis [186]. The inability to noninvasively visualize and 
monitor fibrosis progression impedes the ability to develop and test targeted 
treatments for the attenuation of cardiac fibrosis in this high risk population. 
Visually and quantitatively monitoring cardiac fibrosis over time has applications 
for clinical trials of anti-fibrotic therapies such as spironolactone [170,187] or 
fibroblast growth factor receptor blockade [141,188] as well as patient selection 
for pharmaceutical intervention, radiofrequency ablation, or implantable 
cardioverter-defibrillator placement. Collagen volume fraction from myocardial 
tissue biopsy has been the historical gold standard for detecting and quantifying 
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fibrosis but is prone to false negatives [65] and is undesirable for serial 
measurements. 
Over years of hemodialysis treatment, patients with ESRD have an 
increasing risk of cardiac mortality [185], which may be due to advancing fibrosis. 
We hypothesized that over 1 year, cardiac fibrosis progresses in patients on 
routine hemodialysis for treatment of ESRD, irrespective of structure or function 
alterations. Chapter 3 described a baseline study of fibrosis identification using 
our 2-pt bSSFP method (described in Chapter 2) in patients with ESRD. Here we 
report a 1-year follow up study conducted in a subset of these patients with 
ESRD. We measured the progression of left ventricular (LV) fibrosis using 2-pt 
bSSFP along with structural and functional correlates of heart failure. 
 
Materials and Methods 
Participants 
 All patients with ESRD from our previous study (Chapter 3) were invited to 
return for a second study visit 1 year after their initial scan. Participants were 
considered eligible for this follow up study if they were presently on hemodialysis 
treatment, had no MRI-unsafe implants or devices and had not developed 
arrhythmia (for proper ECG gating of sequences). This study was approved by 
the local Institutional Review Board and all participants were consented for the 
initial study and re-consented for the follow-up, if necessary. Since this was a 
repeated measures design, each patient served as his/her own internal control, 




Cardiac Imaging Protocol and Image Analysis 
 All baseline characteristics were collected during the initial visit for 
completion of this prior study and reported in this chapter only for patients who 
participated in the follow up study visit. All cardiac imaging and offline image 
analysis including structure, function, and strain was completed exactly as 
described in Chapter 3: Materials and Methods. All quantitative analysis was 
completed on raw data from ΔS/So maps. Figures are displayed using a 2x3 
median filter to reduce noise. We used the healthy standard cumulative 
distribution function generated from healthy controls in the initial study (Chapter 
3) as the reference standard for analysis of ΔS/So signal enhancement in follow 
up images. Thus, both baseline and follow up scans were compared against the 
same healthy standard distribution for the calculation of divergence, as a metric 
of fibrotic burden. 
 
Statistical Analysis 
 IBM SPSS Statistics Version 22 (IBM Corp, Armonk, NY) or MATLAB 
(MathWorks Inc., Natick, MA) were used to complete all statistical analyses. 
Paired t-tests were used to compare baseline and follow up measures. Data are 
presented as mean (range) or count (%) where appropriate. All comparisons 







From the initial study, 11 patients were eligible to complete a 1-year follow 
up scan. Of these, 1 patient had received a kidney transplant and discontinued 
dialysis and 4 others declined to participate for medical or other reasons. Six 
patients completed follow up CMR visits for this study. Demographic information 
is detailed in Table 4.1. Primary cause for kidney failure was hypertension (50%), 
diabetes (33%) or unknown (17%). All 6 patients were concurrently hypertensive 
and 4 patients (67%) had Type 2 diabetes. One patient had a failed kidney 
transplant and subsequently started hemodialysis, prior to the baseline scan. 
Average time on hemodialysis was 4.5 years at baseline. All participants 
completed the follow up CMR visit approximately 1 year after the initial visit 
(average=12.3 months since baseline, range: 11.1-14.4 months).  
 
Clinical Cardiac Measures of Structure, Function, and Strain 
 Clinical features at baseline and follow up are detailed in Table 4.2. 
Neither body mass index (BMI) nor body surface area (BSA) was significantly 
changed. On ECG, corrected QT (QTc) interval shortened from 487.5 ± 36.4 ms 
to 439.2 ± 11.3 ms (p<0.05). End diastolic volume (EDV) did not change, but 
there was a trend toward reduced end systolic volumes (from 56.7 ± 26.6 mL to 
47.747 ± 25.0 mL, p=0.053) which contributed to increased ejection fraction (EF) 
from 61.2 ± 8.8% to 65.9 ± 10.4% (p=0.044) over the follow up period. Average 
LV mass, LVMI, septal thickness, and H/R ratio were not significantly changed 
 95 
 
over the follow up year (Figure 4.1), although 5 of the 6 patients demonstrated 
slightly reduced EDV, reduced ESV, and increased EF (Table 4.2). While this 
cohort was hypertrophic at baseline, as a group, LV mass did not significantly 
increase over the follow up period and H/R ratio decreased slightly. Between 
baseline and follow up, changes in circumferential diastolic strain rate (from 174. 
3 ± 45.9%/s to 177.2 ± 52.9%/s, p> 0.05) and longitudinal strain (from -20.6%/s 
to -21.5%, p>0.05) were varied, but not significantly different (Figure 4.2).  
 
Examples of Fibrosis Development 
Among the six individuals recruited to date for a 1-year follow up scan, 
diverse phenotypes were observed with respect to progressive changes in the 
magnitude of cardiac fibrosis. Some patients demonstrated low levels of ΔS/So at 
baseline with progressively increased ΔS/So over time, which is seen in Figure 
4.3. This example patient had received hemodialysis treatment for approximately 
2 years at baseline. Low and uniform ΔS/So values are seen across the LV in 
baseline images (Figure 4.3 A-C). Globally, this patient demonstrates normal 
baseline ΔS/So values throughout the entire myocardium in line with those 
established for healthy controls in Chapter 3 (Figure 4.3 D). At the time of the 
follow up visit, diffusely elevated ΔS/So values were evident across the 3 example 
slices (Figure 4.3 E-G) primarily in basal and septal regions of the heart (Figure 
4.3 H). Divergence increased from 9.8 AU (within the bounds of healthy controls) 
to 27.6 AU (well outside the range of normal values), indicating advanced fibrosis 
progression in this patient. 
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 In contrast to the prior individual, some patients who were imaged 
demonstrated negligible alterations in ΔS/So during the follow up period. Baseline 
scans from another representative patient on hemodialysis (4.3 years) reveal low 
and uniform ΔS/So in example slices (Figure 4.4 A-C) and across the entire LV 
(Figure 4.4 D). In follow up images (Figure 4.4 E-G), minimal ΔS/So elevations 
are detected, mainly in the mid ventricle but not elsewhere throughout the LV 
(Figure 4.4 H). A small increase of 3.9 AU in total LV divergence demonstrates 
the minor progression of fibrosis in this patient. 
 
Longitudinal Monitoring of Fibrosis Progression  
Five patients demonstrated increased ΔS/So (Figure 4.5 A) and 
divergence values (Figure 4.5 B) with an average group increase of 7.1 ± 13.7 
AU in divergence from baseline to follow up. Cumulative distribution functions for 
all patients are shown in Figure 4.5 C. The baseline rightward shifts in ΔS/So 
(quantified by divergence) are visually evident compared to the healthy standard. 
Over the follow up period a further shift in ΔS/So distribution is noticeable for most 
patients, indicating increased fibrosis over time.  
 
Discussion 
 Here we described a small follow up study using non-contrast 2-pt bSSFP 
CMR to monitor fibrosis progression in patients on hemodialysis for treatment of 
ESRD. The rate of sudden cardiac death increases over time with chronic 
hemodialysis [185], indicating that fibrosis may be progressing unchecked, 
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without proper measurement or treatment options for these patients. LGE CMR 
has become the clinical standard to identify for focal fibrosis and with the addition 
of T1 mapping can detect diffuse fibrosis through calculation of the extracellular 
volume content [77]. The exclusion from gadolinium enhanced CMR, however, 
has severely limited the ability to detect, monitor, and treat fibrosis progression in 
patients with ESRD.  
While risk of cardiac mortality increases with time on chronic 
hemodialysis, we have previously shown that fibrotic burden does not directly 
correlate with hemodialysis vintage (Chapter 3). This is evident in the example 
participants in this study. At follow up, the patient in Figure 4.3 had received 
hemodialysis treatment for 3 years and demonstrated a large fibrotic burden, 
compared to over 5 years of treatment for the patient in Figure 4.4, who had a 
lower fibrotic burden. This lack of association is consistent with a previous 
gadolinium based CMR study, which found no correlation between fibrotic burden 
and hemodialysis vintage [58]. So while chronic hemodialysis increases mortality 
risk over time, it is necessary to delineate the etiology by determining whether 
fibrosis is progressing in the individual patient. 
Since cardiac structural [51,56-58] and functional [60,90] alterations are 
highly prevalent in the ESRD population, increased hypertrophy and reduced LV 
function have been used as surrogate indicators of cardiac fibrosis. While 
prognostic in the cardiac and ESRD populations, it is unclear whether these 
associate specifically with fibrosis. In fact, fibrosis may precede hypertrophy in 
some patients [34]. In this study we showed pervasive progression of fibrosis in 
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our patients with ESRD over 1 year (Figure 4.5) without concurrent alterations in 
hypertrophy (Figure 4.1), strain (Figure 4.2), or ejection fraction (Table 4.2). It is 
surprising that while fibrosis increased, the typical indicators of heart failure 
progression—reduced contractility and EF—did not change over this follow up 
period. Thus we may be able to distinguish small variations in fibrosis before a 
patient has advanced to LV stiffness severe enough to be detected by other 
clinical measures. 
It is clear that the development of hypertrophy should be considered a 
separate disease process from fibrosis progression. Moreover, deterioration of 
LV function may only arise after advanced cardiac disease progression, well after 
high levels of fibrosis have developed. Thus identification of fibrosis, independent 
of structural or functional deficits, could improve prognosis for patients with 
ESRD [51].  
Patterns of fibrosis have been previously described in hemodialysis 
patients [58,59], prior to the ban on gadolinium use. Gadolinium free replication 
of these results is now possible and could aid in the understanding of both global 
and focal patterns of disease, while monitoring changes over time. Global fibrotic 
burden determination may assist in overall cardiac risk stratification [51], however 
the visualization of potentially arrhythomogenic fibrotic foci could improve 
selection for alternative therapies such as radiofrequency ablation and 
implantable cardioverter defibrillators. While nearly 40% of all ESRD deaths are 
attributable to arrhythmia and sudden cardiac death, less than 1% of the 
hemodialysis population receives implantable defibrillators or resynchronization 
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therapies [185]. Noninvasive and safe detection of fibrotic patterns in patients 
with ESRD may assist in tapping these underutilized and potentially lifesaving 
treatment options to improve the high rates of sudden cardiac death. 
 While overwhelming increases in ΔS/So and divergence were evident in 
this study, a small sample size has limited the ability for us to detect statistically 
significant elevations in fibrosis. Measurement of fibrosis progression in patients 
on hemodialysis warrants further investigation with a larger sample and multiple 
time points. Future analyses should examine the magnitude of change in fibrosis 
and correlations to advancing hypertrophy, dilation, or ventricular stiffness in 
patients with ESRD. We were also limited by the need for 2 consecutive breath 
holds to acquire pairs of images for the 2-pt bSSFP method. Alterations in breath 
hold position can introduce misalignment of the myocardium. While we manually 
corrected for these shifts, it is possible that erroneous voxels from the blood pool 
or pericardium were included in these analyses. 
 In conclusion, we have shown that patients on hemodialysis for ESRD 
nearly ubiquitously developed increased fibrotic burden, even in a short 1 year 
period. Fibrosis development is independent of alterations in hypertrophy or 
deteriorating contraction or relaxation. The ability to safely monitor patients with 
ESRD without the use of gadolinium may assist in more comprehensive risk 
stratification, improved treatment selection, and eventually a reduction in cardiac 
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Table 4.1. Baseline Participant Demographics. 
Variable Result 
Age (yrs) 54.2 (31.2-79.7) 
Male 3 (50) 
White 2 (33) 
Black/African American 4 (67) 
Hemodialysis vintage (yrs) 4.5 (2.0-7.5) 
Systolic Blood Pressure (mmHg) 160 (144-182) 
Diastolic Blood Pressure (mmHg) 85 (65-98) 
Primary Cause of ESRD  
   Hypertension 3 (50) 
   Diabetes 2 (33) 
   Unknown/Unsure 1 (17) 
Comorbidities  
   Hypertension 6 (100) 
   Diabetes 4 (66) 
Numerical variables are presented as mean (range). 







Table 4.2. Clinical Cardiac Measurements. 
Variable Baseline Follow Up p 
Heart Rate (bpm) 71.8 (59-91) 67.8 (54-86) 0.303 
BMI (kg/m2) 31.6 (27.3-39.1) 31.6 (27.3-38.1) 0.934 
BSA (m2) 2.1 (1.8-2.2) 2.1 (1.8-2.3) 0.896 
QRS Duration (ms) 90 (76-98) 90 (78-100) 0.681 
QTc Interval (ms) 487.5 (444-518) 439.2 (427-456) 0.050* 
EDV (mL) 140.6 (95.0-214.0) 131.8 (88.1-185.5) 0.114 
ESV (mL) 56.2 (24.9-96.4) 47.7 (18.0-76.2) 0.053 
EF (mL) 61.2 (48.6-73.8) 65.9 (52.0-79.6) 0.044* 
Cardiac Output (L/min) 6.1 (4.4-8.1) 5.7 (4.5-7.3) 0.419 
LV Mass (g) 222.4 (160.9-287.6) 208.4 (163.0-260.1) 0.135 
LVMI (g/m2) 110.3 (86.2-130.5) 102.6 (93.2-118.1) 0.157 
Septal Thickness (cm) 1.3 (1.1-1.6) 1.2 (1.0-1.5) 0.565 
H/R Ratio 0.5 (0.3-0.6) 0.4 (0.3-0.5) 0.138 
Data are presented as mean (range). BMI: body mass index, BSA: body surface 
area, QTc: corrected QT (standardized to 60 beats per min), EDV: end diastolic 
volume, ESV: end systolic volume, EF: ejection fraction, LV: left ventricle, LVMI: 
left ventricular mass index (indexed to BSA), H/R ratio: septal thickness/chamber 







Figure 4.1. Hypertrophy did not progress over time in patients with ESRD. 
Patients with ESRD had elevated (A) LVMI, (B) interventricular septal thickness, 
and (C) H/R ratio at baseline but no significant alterations in these measures of 






Figure 4.2. Measures of contraction and relaxation. (A) Circumferential peak 
strain and (B) diastolic strain rate show varied, but not significant changes from 
baseline to follow up in patients with ESRD. (C) Peak strain and (D) diastolic 
strain rate in the longitudinal direction showed no significant changes over time. 






Figure 4.3. Representative patient with large increases in fibrosis. 
Representative ΔS/So maps at the (A) base, (B) mid ventricle, and (C) apex of a 
patient on hemodialysis for ESRD. (D) The bullseye plot revealed low ΔS/So 
values across the entire ventricle in this patient at baseline. At the follow up visit, 
ΔS/So maps demonstrated elevations in the (E) base and septal regions of the 
(F) mid ventricle and (G) apex of the LV. (H) Diffuse elevation was evident across 
many slices of the LV, indicating that this patient had developed significant 
amounts of fibrosis over the follow up period. Divergence increased by 22.0 AU 





Figure 4.4. Minimal increases in fibrosis over time. At baseline, ΔS/So maps 
from this representative patient revealed minor scattered enhancement patterns 
in (A) basal, (B) mid ventricular, and (C) apical slices. (D) Average ΔS/So values 
remained low across the entire ventricle in this patient. At follow up, myocardial 
ΔS/So remained low in the (E) base and (G) apex, with some increased values 
developing in the (F) mid ventricle. (H) The corresponding bullseye plot 
demonstrated patterns of minor elevations in this patient. Across the 2 study 







Figure 4.5. Measurements of increased fibrosis in patients with ESRD.  (A) 
Whole ventricle ΔS/So values increased in all but 1 patient from baseline to follow 
up. (B) Divergence values increased in all but 1 patient, indicating a greater 
rightward shift in the distribution of ΔS/So values and increased fibrotic burden 
over time. (C) Cumulative distribution functions of the healthy simulated standard 
(gray), baseline (black), and follow up scans (red). All patients were shifted from 
the healthy standard at baseline, corresponding to an increased fibrotic burden 
compared to healthy individuals. All but 1 patient demonstrated a greater shift at 
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CHAPTER 5: CONCLUSIONS AND PERSPECTIVES 
 
Summary of Key Findings 
Contrast-enhanced CMR has become an invaluable tool for myocardial 
tissue characterization, advancing our ability to detect and monitor various forms 
of fibrosis [64,69-71,74,88]. Unfortunately, the risk of developing nephrogenic 
systemic fibrosis has limited the use of gadolinium in individuals with reduced 
kidney function [84-86]. This exclusion has thwarted the ability to use our most 
powerful CMR techniques in patients with ESRD, who are at high risk of 
developing myocardial fibrosis [51,58], arrhythmias, heart failure, and sudden 
cardiac death [185]. Without a suitable diagnostic technique, the ability to 
understand underlying mechanisms of heart failure in ESRD is hindered, further 
limiting the development and testing of appropriate therapeutics. A gadolinium 
free and quantitative method for fibrosis detection could overcome these 
obstacles and offer a suitable diagnostic and monitoring option with applications 
in trials of new therapeutics. The projects in this dissertation have described the 
development of a quantitative gadolinium-free CMR technique, subsequent 
measurement of cardiac fibrosis in patients with ESRD, and a preliminary study 
in longitudinal monitoring of changes in cardiac fibrosis in ESRD patients.  
 Following previous development in a mouse model of experimentally 
induced myocardial infarction [111], we translated 2-pt bSSFP CMR to a cohort 
of 47 cardiac patients referred for standard of care LGE CMR plus 10 healthy 
age-equivalent controls (Chapter 2). Using high and low MT-weighted cine 
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bSSFP image pairs, we were able to extract endogenous contrast from the 
alterations in magnetization transfer (MT) arising from extracellular matrix 
remodeling. 2-pt bSSFP identified areas of necrosis and edema in acute 
myocardial infarction (Figure 2.2), replacement fibrosis in chronic myocardial 
infarction (Figure 2.4), and reactive fibrosis in non-ischemic dilated 
cardiomyopathy (Figure 2.5). Along with T1 and T2 times, ΔS/So was elevated in 
regions of enhancement at LGE compared to myocardium without enhancement 
(Figure 2.7). Using gadolinium partition coefficient (GPC) as a contrast based 
standard for fibrosis quantification, there was a stronger correlation with ΔS/So 
(R=0.82) than with other non-contrast techniques (Figure 2.8). There was strong 
agreement in percent of enhanced myocardium (R2 = 0.84) and transmurality of 
enhancement (R2 = 0.73) between 2-pt bSSFP and LGE techniques (Figure 2.9). 
Agreement was also achieved during subjective assessment by blinded 
reviewers of ΔS/So maps compared to LGE images (Figure 2.8), with a few cases 
of false positive (Figure 2.10) and false negative (Figure 2.11) identification of 
enhancement. Representing a known limitation of LGE CMR, small patterns of 
subendocardial signal enhancement were missed in 4 patients using ΔS/So 
maps. Time limitations restricted us to the acquisition of only 1 mid ventricular 
slice in this cohort, which may have also missed areas of enhancement in some 
patients’ hearts. 
 Extending 2-pt bSSFP to patients on hemodialysis for ESRD, Chapter 3 
detailed visual and quantitative fibrosis detection without gadolinium along with 
correlations to blood biomarkers that are commonly used to assess ischemia, 
 110 
 
cardiac remodeling, and extracellular matrix turnover. We imaged the entire LV of 
29 patients with ESRD and 33 healthy controls of similar age using 2-pt bSSFP 
CMR. While we found no differences in ejection fraction nor diastolic strain rate 
and only small decreases in global longitudinal strain (Table 3.1, Figure 3.3), 
there was widespread LV hypertrophy in the ESRD group (Figure 3.8). Using 
cumulative distribution function analysis, we quantified the extent of ΔS/So signal 
elevation, to represent a metric of fibrotic burden. Patients with ESRD 
demonstrated increased fibrotic burden (divergence=9.8 AU [6.0, 23.6]) 
compared to controls (4.7 A.U. [1.2, 11.5], p = 0.003). We identified 3 patterns of 
fibrosis without gadolinium (Figure 3.6) that were previously described using LGE 
[59] in patients with ESRD. Hypertrophy demonstrated only a modest correlation 
with fibrosis, while strain did not correlate with fibrosis at all (Figure 3.9). The 
existing dogma in the field of heart failure in ESRD patients dictates that 
hypertrophy and strain are robust surrogate markers of fibrosis because of the 
increased tensile characteristics of fibrotic tissue. Our findings offer compelling 
evidence that structural and functional measures are not sensitive to diffuse 
extracellular matrix remodeling and interstitial fibrosis. We utilized our capacity to 
identify fibrosis to compare fibrotic burden with blood biomarkers of cardiac 
stress, ischemia, and extracellular matrix turnover. TnT, FGF23, PTH, and TIMPs 
were elevated in patients with ESRD (Table 3.3). The interplay between 
hypertrophy and fibrosis was evident in biomarker analysis, as the commonly 
employed TnT and FGF23 displayed stronger correlations to hypertrophy than 
fibrosis in our cohort. TIMPs, however, were moderately correlated with fibrosis 
 111 
 
but showed no association with hypertrophy. With the ability to distinguish 
between hypertrophy and fibrosis, imaging guided biomarkers such as TIMPs 
may emerge as fibrosis-specific diagnostic measures and therapeutic targets for 
patients with ESRD. 
 Extension of our findings for the purpose of longitudinal monitoring is 
described in Chapter 4 where a preliminary study to detect progression of fibrosis 
over time was performed in patients on hemodialysis for ESRD. Patients from the 
study in Chapter 3 were asked to return for a follow up exam using 2-pt bSSFP 
CMR. Six patients completed the follow-up exam. These patients were 
overwhelmingly hypertensive and hypertrophic at baseline (Table 4.1). Over the 
follow up period, they demonstrated increased EF (61.2 ± 8.8% to 65.9 ± 10.4%, 
p=0.044) but with no corresponding increases in hypertrophy (Table 4.2, Figure 
4.1) nor decreases in strain measurements (Figure 4.2). Although no clinically 
relevant alterations in structure or function were identified, all but 1 patient 
demonstrated an increase in fibrosis over the 1 year follow up period (Figure 
4.5). Fibrotic burden and progression may add prognostic value above and 
beyond the minimal alterations seen in structure and function to aid in risk 
stratification and therapeutic selection for patients on hemodialysis. 
Non-contrast CMR techniques for measurement of fibrosis will empower 
the investigation of noninvasive biomarkers, molecular targets, and treatment 
efficacy in patients with ESRD. Unlike LGE, 2-pt bSSFP can detect both focal 
and diffuse disease patterns using a single technique while simultaneously 
providing images for clinically important structural and functional measures. We 
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are more directly measuring fibrosis in cardiac and kidney patients than the 
options currently available to patients with ESRD. We have also challenged the 
current dogma and provided evidence that structural and functional alterations 
may not be sensitive to the development of interstitial fibrosis which is a critical 
substrate for arrhythmias and sudden cardiac death. 
 
Clinical Perspective 
Myocardial tissue biopsy has served as the standard for fibrosis detection 
via calculation of the collagen volume fraction, primarily in epicardial tissue 
samples. Without the use of contrast enhanced CMR, biopsy is the only reliable 
alternative for fibrosis measurement in patients with ESRD. Unfortunately, biopsy 
is prone to underreporting true fibrotic burden [65], obligates clinicians to 
extrapolate the fibrotic content of non-sampled regions, and is invasive and 
undesirable for repeated measurements. With 2-pt bSSFP CMR, we have the 
ability to observe spatiotemporal changes in the magnitude and pattern of fibrosis 
across the entire LV in a way that is not possible with biopsy nor safe with 
gadolinium enhanced CMR.  
Fibrosis development is a dynamic process that requires complex 
molecular cues with unique patterns of activation in order to reorganize existing 
extracellular matrix and increase collagen production by fibroblasts [26]. Specific 
molecular players in these processes could serve as biomarkers of fibrosis 
development and potential treatment targets for attenuation or prevention of 
fibrosis. Since hypertrophic and fibrotic remodeling often occur in tandem for 
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patients with ESRD, the etiology of cardiac disease development is complex. 
Using 2-pt bSSFP we are now able to begin untangling the fibrotic disease 
process from structural alterations and investigate the specific underlying 
mechanisms and appropriate biomarkers of fibrotic remodeling. For instance, 
TnT is widely used to indicate recent myocardial infarction and cardiomyocyte 
death, but is often detected in patients with ESRD [189], indicating myocardial 
damage from non-ischemic causes. Some have suggested a correlation between 
elevated TnT and fibrosis in non-ischemic cardiomyopathy [190] and prognostic 
value in ESRD [189,191]. Our results indicate that while TnT correlates with 
fibrosis it also correlates with hypertrophy. While it may be prognostic, TnT is 
unsuitable as a fibrosis-specific biomarker and may instead reflect a combination 
of structural hypertrophy and fibrosis development. Similarly, FGF23 has been 
explored as molecular mechanism [53,141,192,193], biomarker [159,194], and 
therapeutic target [141,169] of remodeling in patients with ESRD. It has been 
extensively correlated with hypertrophy, as we have also shown, yet is also 
associated with fibrosis detected by 2-pt bSSFP, rendering FGF 23 unable to 
distinguish fibrosis from the associated—but independent—hypertrophic 
remodeling process. 
The extracellular matrix remodeling process offers alternate molecular 
targets that may be more specific to fibrosis development. 2-pt bSSFP allows us 
to probe the relationship between MMPs, TIMPs, fibrosis, and heart failure in 
ESRD in a safe, noninvasive way. In fact, we have found that TIMPs correlated 
with fibrosis but not hypertrophy, which offers promising evidence that these 
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peptides may be more specific to fibrosis. Investigations are emerging for the use 
of MMP inhibition to attenuate cardiac fibrosis development in animal models of 
ESRD [180,195]. 2-pt bSSFP could serve as a method to both interrogate 
biomarkers of extracellular matrix turnover and eventually determine the efficacy 
of emerging treatments, such as exogenous MMP inhibitors, that are currently 
under consideration. 
 
Limitations and Future Opportunities 
A few pertinent limitations are present across these studies, which 
represent important opportunities for future investigations. As with most CMR 
acquisitions, 2-pt bSSFP requires patients to sustain multiple end-expiratory 
breath holds. In addition, to achieve maximal resolution we attempt to minimize 
voxel size, which can require lengthy breath hold time. Due to need for 2 
separate images to complete the 2-pt bSSFP method, the total number of breath 
holds and length of time can be limiting for some patients. To begin addressing 
breath hold limitations, our lab has investigated the use of 3 dimensional (3D) 
cine bSSFP. 3D bSSFP allows for the acquisition of a slab of multiple short axis 
slices, spanning a larger portion of the left ventricle during a single breath hold. 
This technique has the potential to reduce the total number of breath holds while 
maintaining myocardial steady state signal and collecting data across the whole 
LV (Figure 5.1). Future investigations could adapt 3D bSSFP to acquire slabs at 
flip angles of 5° and 45° for use in 2-pt bSSFP fibrosis imaging with the benefit of 
reduced number and total time of breath holds. 
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Between the 2 image acquisitions for 2-pt bSSFP, there is a possibility for 
patient motion or inconsistent breath holds leading to misalignment of the 
myocardium in the image pair. If the myocardium is not aligned, voxels outside of 
the myocardium could be included in the analysis of MT and erroneously alter the 
measured fibrotic burden. As described in chapters 3 and 4, we manually 
registered any image pairs that were not aligned. While this allowed us to 
salvage many slices for image analysis, it is possible we introduced other noise 
into our analysis. Ideally, a non-contrast imaging technique would achieve 
magnetization transfer weighting in a single image, requiring only 1 breath hold 
per slice position. Stemming from the need to create better contrast between 
endocardial scar and blood pool in LGE images (discussed in Chapter 2), new 
techniques are emerging for dark-blood imaging during LGE, using Flow-
Independent Dark-blood DeLayed Enhancement (FIDDLE) [196] and T1(Rho) 
And Magnetization transfer and INvErsion Recovery (TRAMINER) sequences 
[197,198]. In their current uses, these sequences null the blood pool to turn it 
black, which allows for enhancement at LGE—especially near the blood pool—to 
become more easily visualized after injection of gadolinium. As evident within the 
name TRAMINER, these imaging sequences incorporate an MT preparation 
scheme that encodes MT within the image. When modified and used without 
gadolinium, TRAMINER can extract endogenous contrast via MT weighting 
within a single image and therefore single breath hold (Figure 5.2). Studies within 
our lab are comparing TRAMINER to LGE in cardiac patients, including patients 
with myocardial infarction (Figure 5.2), who are referred for gadolinium based 
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CMR. If successful, these preliminary TRAMINER studies could be extended to 
non-contrast fibrosis imaging in ESRD patients while lowering the breath hold 
burden and eliminating image registration issues that currently exist in our 
current techniques. This technique has the added benefit of reducing manual 
image correction and post processing time, which are important when evaluating 
clinical patients in near real time and for future ambitions to automate image 
analysis. 
Sub-endocardial scar identification has been a challenge in LGE CMR due 
to the low contrast to noise present when a scar is near the bright signal from 
blood. This has been the motivation for development of FIDDLE [196] and 
TRAMINER [198] described above. Similar limitations exist in 2-pt bSSFP CMR 
and were discussed in Chapter 2 and presented in Figure 2.11. Another example 
arose in the study from Chapter 3 and is presented in Figure 5.3. This patient 
had a history of known myocardial infarction with comorbid hypertension, type 2 
diabetes mellitus, and ESRD which requires hemodialysis. Thus, this patient 
could not complete gadolinium based CMR to monitor stability of the established 
replacement fibrosis nor the presence or progression of additional reactive 
fibrosis. Wall thinning is ready apparent in this patient, but it is difficult to define a 
fibrotic scar, due to its location near the blood pool. Future development of 
magnetization transfer imaging will need to address this issue. One possible 
option is to mask the myocardium (as shown in Figure 5.2 B and D) to only 
present voxels of interest within the LV. This is limited by the contrast achieved in 
anatomical images (e.g. Figure 5.3 A) and accuracy of manual region of interest 
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definition, and removes other anatomical features for reference. While the CMR 
field is moving to improve the contrast between myocardium and blood pool in 
LGE, MT CMR must go in parallel to limit the uncertainty in sub-endocardial scar 
identification. Importantly, similar to extracellular volume (ECV) calculation, MT 
CMR has the advantageous ability to image multiple types of fibrosis within 1 
imaging technique, as seen in Figure 5.3 B, but without the need for gadolinium. 
This is crucial for monitoring patients with prior myocardial infarction who may 
develop diffuse reactive fibrosis in remote regions [31,32] and for patients with 
multiple risk factors, like those with ESRD, who are at high risk for both ischemic 
and non-ischemic fibrosis development [58,59] but who cannot receive 
gadolinium. 
 
Additional Future Directions 
  As 2-pt bSSFP continues to develop, it will be important to assess the 
practical clinical utility of this technique and its ability to recapitulate findings from 
gadolinium based CMR techniques. In our initial clinical study (Chapter 2) ΔS/So 
was highly correlated with gadolinium partition coefficient (R=0.82) and blinded 
reviewers with only minimal training were correctly able to identify elevations in 
ΔS/So with about 73% agreement to LGE. This was in a sample of patients with 
known cardiac disease, demonstrating a variety of fibrosis patterns. It will be 
important to determine whether 2-pt bSSFP can be used diagnostically to identify 
previously unknown cardiac disease in patients at risk for developing fibrosis. In 
the ESRD population, there is a high prevalence of diffuse interstitial fibrosis [51]. 
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This pattern is difficult to identify with LGE [63], but can be identified with T1 
mapping techniques through ECV calculation [74-76] for patients in which it is 
safe to deliver gadolinium. We are currently investigating the ability for 2-pt 
bSSFP to identify diffuse fibrosis comparable to ECV in patients with type 2 
diabetes with no history of myocardial infarction nor reduced kidney function. 
These patients often develop expanded ECM [199] and diffuse myocardial 
fibrosis but are still able to receive gadolinium contrast. Importantly, type 2 
diabetes is a leading risk factor of ESRD [185] so these patients have similar 
medical conditions and comorbidities to many patients with ESRD and may in 
fact experience renal complications in the future. While this group is more 
homogenous than patients included in Chapter 2, they likely have a less 
established cardiac history with less predictable fibrotic burden. We have 
scanned 30 patients with type 2 diabetes mellitus and 10 age equivalent healthy 
volunteers using 2-pt bSSFP and pre and post-contrast T1 mapping (Figure 5.4). 
There are no differences in standard clinical measures of structure and function 
between groups but preliminary analysis shows promise for elevated ΔS/So, 
native T1, and ECV in the diabetes group. With blinded review, we will now be 
able to compare 2-pt bSSFP, native T1 mapping, and ECV quantification across 
the entire LV for the de novo identification of diffuse fibrosis. It is important that 2-
pt bSSFP perform well against current standard contrast techniques both 
quantitatively and subjectively if it is to progress toward clinical utility, especially 




We are also interested in utilizing 2-pt bSSFP to begin understanding the 
exceedingly high death rates experienced at the initiation of hemodialysis in 
patients with ESRD. There is a severe peak in all cause and cardiac mortality at 
month 2 of hemodialysis [185], with a currently unknown cause. Due to the 
drastic, hyperphysiologic alterations in hemodynamics [90] we speculate that 
early cardiac remodeling and acute fibrosis development might be a risk factor in 
this early timeframe. Future studies could utilize 2-pt bSSFP in a large cohort of 
ESRD patients who plan to initiate hemodialysis. Imaging before and at multiple 
time points within the first year of treatment initiation would offer evidence of 
early cardiac fibrosis development—with or without concomitant structure or 
function alterations—that could be compared to clinical measures of structure 
and function. Cardiac outcomes such as development of arrhythmia, heart 
failure, and sudden cardiac death within the first year could be correlated to 
fibrosis development to begin to understand the potentially modifiable risk factors 
in this critical period for patients beginning hemodialysis. 
Blood biomarkers are a promising but complex opportunity for diagnostic 
and therapeutic targets in the ESRD population. With limited sample sizes in our 
current study (Chapter 3), analyses of blood biomarkers and their correlations 
with fibrosis and hypertrophy are modest but promising. Markers of extracellular 
matrix remodeling such as MMPs and TIMPs may prove to be more specific to 
cardiac fibrosis than the currently employed TnT, FGF23, and PTH which are 
confounded by hypertrophy. Larger cohorts of ESRD patients are necessary for 
more complex multiple correlation analysis to parcel out the interaction between 
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hypertrophy, fibrosis, and individual biomarkers. While MMPs and TIMPs are 
imbalanced in patients with ESRD compared to healthy individuals and CKD 
patients prior to hemodialysis [148], studies have reported both increases 
[146,181,182,200] and decreases [148] in these peptides compared to healthy 
controls. This may be a manifestation of the heterogeneous pathophysiology of 
cardiac fibrosis in this population. Additional studies are warranted to begin 
understanding whether MMP or TIMP concentrations are indicative of either 
replacement or reactive fibrosis separately. There is evidence that MMPs and 
TIMPs are associated with worsening, but not end stage, heart failure [144]. 
Serial measurements of these peptides in ESRD patients along with longitudinal 
monitoring of cardiac structure, function, and fibrosis by CMR would provide 
evidence for the utility of these biomarkers as predictors of heart failure risk and 
potential molecular treatment targets for the attenuation of cardiac fibrosis. 
 
Final Remarks 
The development of 2-pt bSSFP as a non-contrast CMR technique has 
the potential to improve the understanding of heart failure in the context of 
ESRD. This safe and noninvasive technique could empower future investigations 
for advanced diagnostics and molecular treatment targets for cardiac fibrosis. We 
have successfully begun to recapitulate findings from gadolinium based CMR for 
quantitative and subjective identification of cardiac fibrosis in patients on 
hemodialysis for ESRD. The current challenges in patient burden and post 
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processing methods represent vital opportunities for improvements in non-




Figure 5.1. 3D bSSFP image acquisition and signal evolution. (A) Long axis, 
4-chamber end diastolic image of the heart with a superimposed schematic of the 
slab (solid box) and slice (dashed line) architecture for one representative slab. 
(B) Normalized signal intensity waveforms for all six slices in one 3D slab are 
shown throughout the entire cardiac cycle. Solid lines represent the middle two 
slices (slice 3 and 4) which maintained the best steady state throughout the 




Figure 5.2. Fibrosis imaging using a single breath hold magnetization 
transfer weighted sequence.  (A) A long axis (4-chamber) image acquired with 
the clinical standard LGE-CMR in a patient who suffered a myocardial infarction. 
Significant enhancement was evident in the apex of the LV. (B) Using a threshold 
technique (similar to Chapter 2), myocardial voxels 2 standard deviations above 
the average, remote (non-enhanced) myocardial signal were presented in white, 
overlayed on all myocardial voxels in gray. (C) A similar long aixs view was 
acquired in this patient using a non-contrast, magnetization-transfer weighted 
sequence (TRAMINER) in a single breathhold, which revealed significant 
elevations in the LV apex. (D) Similar to B, voxels with signal values 2 standard 
deviations above the mean were displayed as white with other myocardial voxels 
in gray. The image aqcuired without contrast using the TRAMINER technique 
showed extremely good spatial agreement with LGE, identifying areas of 
edematous and necrotic tissue folowing myocardial infarction. TRAMINER may 






Figure 5.3. Mixed subendocardial scar and diffuse fibrosis in chronic 
myocardial infarction.  (A) Example bSSFP image from a patient who suffered 
a previous myocardial infarction, which was apparent in a large area of severe 
myocardial thining (arrow). This patient was also hypertensive, diabetic, and was 
on hemodialysis for ESRD and therefore would be excluded from LGE CMR. (B) 
It was diffucult to detect a subendocardial pattern of focal scar in the 
corresponding ΔS/So map. Contrast between the blood pool and adjacent 
elevations in myocardial signal are a limitation of 2-pt bSSFP, as well as other 
CMR techniques. The ΔS/So map revealed areas of diffuse enhancement in this 
patient that would not be detectable by LGE, however. (C) The T1 map reveals 
widespread enhancement, however the myocardium, especially in areas of 
thinning, is difficult to resolve. While many CMR techniques share similar 
limitations, 2-pt bSSFP may be able to detect both focal and diffuse fibrosis in the 






 Figure 5.4. Image acquisitions in a patient with diabetes. (A) ΔS/So map 
generated at a mid ventricular slice using 2-pt bSSFP in a patients with type 2 
diabetes. This patient demonstrated diffuse enhancement in this and other slices 
across the LV. (B) Elevations in T1 are apparent in the native T1 map acquired at 
the same slice position. (C) Fifteen minutes post-injection of gadolinium, a post-
contrast T1 map was aquired. Maps of pre and post-contrast T1 (B and C) are 
compared to calculate GPC and ECV, the predominant method under 















APPENDIX: LIST OF ABBREVIATIONS 
 
2-pt bSSFP two point balanced steady state free precession 
BMI  body mass index 
bSSFP balanced steady state free precession  
CKD  chronic kidney disease 
CMR  cardiac magnetic resonance imaging 
CVD  cardiovascular disease 
ECG  electrocardiogram 
Echo  echocardiography 
ECV  extracellular volume (fraction) 
EDV  end diastolic volume 
EF   ejection fraction 
ESRD  end stage renal disease 
ESV  end systolic volume 
FGF  fibroblast growth factor 
FIDDLE Flow-Independent Dark-blood DeLayed Enhancement  
GPC   gadolinium partition coefficient 
LGE   late gadolinium enhancement 
LVMI  left ventricular mass index 
MMP  matrix metalloproteinase 
MOLLI modified Look Locker imaging 
MRI  magnetic resonance imaging 
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MT   magnetization transfer 
PTH  parathyroid hormone 
RF  radio frequency 
ROI  region of interest 
SD  standard deviation 
TE  echo time 
TIMP  tissue inhibitor of metalloproteinase 
TnT  troponin T 
TR  repetition time 
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